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ABSTRACT 
 Visceral leishmaniasis (VL) caused by certain species of the genus Leishmania results 
in a significant disease burden worldwide. This is most pronounced in some of the world’s 
poorest communities. In South America and the Mediterranean basin, dogs are the major 
domestic reservoir for Leishmania infantum, one cause of human VL. In addition, dogs 
infected with L. infantum have an immune response and pathophysiology similar to human 
cases, making them a representative naturally-occurring animal model of VL. Chronic 
infection with Leishmania infantum can result in asymptomatic infection for a long period of 
time, or symptomatic, potentially life-threatening visceralizing disease. Immunopathology 
that contributes to the precipitation of clinical disease during natural infection is incompletely 
understood.  The goal of the research presented in this thesis was to evaluate 
immunopathology potentially contributing to the onset of symptomatic VL and to evaluate a 
potential candidate for canine vaccination against Leishmania infantum. Using a prospective 
cohort of dogs naturally infected with L. infantum, we identified the presence of both CD4+ 
and CD8+ T cell exhaustion during symptomatic VL, mediated through coinhibitory receptor 
Programmed Death 1 (PD-1). Blockage of the interaction of PD-1 and one of it’s ligands, B7 
homolog 1 (B7.H1), partially recovered proliferation and IFN production in both CD4+ and 
CD8+ T cells. Furthermore, the blockage of PD-1/B7.H1 improved superoxide production in 
canine monocyte-derived phagocytes, and resulted in improved parasite clearance from 
peripheral blood after 7 days of culture. This data significantly contributes to knowledge of 
immunopathology during VL. In dogs with Leishmania-associated glomerulopathy, we 
evaluated glomerular lesions, describing the occurrence of a type I membranoproliferative 
glomerulonephritis, with expansion of the mesangium and podocyte retraction with 
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mesangial cell interposition. These lesions were associated with glomerular deposits 
containing L. infantum antigen, IgG, and to a lesser extent, complement protein C3b. 
Symptomatic disease was associated with increased glomerular Nod-like receptor protein 3 
(NLRP3) and increased positivity for the  autophagy marker Microtubule-associated protein 
light chain 3 (LC3). This research expands the characterization of Leishmania-associated 
glomerulonephropathy, and the presence of inflammasome activation and autophagy during 
immune complex glomerulonephritis. The final chapter of this thesis evaluates a vaccine 
candidate for prevention of canine leishmaniasis. This research demonstrates the 
immunogenicity of this vaccine candidate after administration.  As a whole, the work 
presented herein is a significant advancement of the understanding of the pathophysiology 
and immunopathology of canine infection with Leishmania infantum with potential correlates 
to human VL, and a report of the immunogenicity of a potential canine leishmaniasis 
vaccine. 
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CHAPTER 1 
LEISHMANIASIS: GENERAL INTRODUCTION 
Kevin J. Esch and Christine A. Petersen 
Excerpt from a manuscript published in Clinical Microbiology Reviews [1]
1
, and a excerpts 
from book chapter to be submitted as a book chapter in Pathobiology of Human Disease: A 
Dynamic Encyclopedia of Disease Mechanisms
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INTRODUCTION
1 
 There are over 77 million dogs and 93 million cats in our households in the United 
States alone.  Approximately 62% of households have at least one pet and over half of these 
have multiple pets (APPA) [2].  Various studies have demonstrated the importance of pets in 
overall health, well-being, and for providing social support [3-6].   Consistent with this 
devotion to pets, owners in the US spend approximately $10.94 billion annually on pet 
supplies and over-the-counter pet medications and $14.11 billion on veterinary care annually 
[2].  Given the number of companion animals in the United States and the bond with their 
owners, awareness and prevention of the zoonotic diseases of our companions is of 
paramount importance.  Protozoal diseases, such Chagas’ disease and leishmaniasis, are 
insidious with high numbers of asymptomatic animals able to transmit disease.  Giardia 
duodenalis and Toxoplasma gondii, endemic to the United States, have a high prevalence in 
companion animals [7, 8] (Figure 1.1).  Leishmania species and Trypanosoma cruzi are 
regional and have a low prevalence within the United States, but are significant sources of 
human disease world-wide and are re-emerging and expanding their geographic distribution 
in companion animals in the United States [9, 10].  Thankfully, we are generally protected by 
intact immune systems and our health is bolstered by good nutrition, sanitation and hygiene, 
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but immunocompromised individuals, including the growing number of obese and/or diabetic 
individuals in the United States are at much higher risk for developing any zoonosis [11, 12].  
 
Figure 1.1. Areas endemic for Leishmania species 
 
As such, awareness of these often neglected diseases in veterinary and human health 
communities is important for protecting pet health and preventing human disease.  In this 
article, we will review mechanisms of virulence, epidemiology, transmission, and clinical 
signs of zoonotic protozoal pathogens of consequence to pet owners in the United States. 
 
LIFE CYCLE AND MECHANISMS OF VIRULENCE
1 
 Leishmaniasis is a vector borne disease caused by species of Leishmania from the 
family Kinetoplastidae.  Infection with Leishmania spp. can result in a spectrum of clinical 
disease dependent upon the infecting species.  Visceral Leishmaniasis (VL) is caused by 
L.infantum in the Americas and Mediterranean basin, and L. donovani in India, sub-Saharan
 
 
  
3
 
Table 1.1. Geographic locations, hosts and companion animal seroprevalence of Leishmania spp. 
Disease entity Species Area(s) of endemicity Predominant reservoir(s) Canine seroprevalence Reference(s) 
Cutaneous 
Leishmaniasis 
Leishmania major Middle East, northwestern China, 
Northwestern India, Pakistan, Africa 
Gerbil species, Jird, Fat 
Sand Rat 
Egypt, 3 cases, Saudi Arabia. 3 
cases 
[13-20] 
 L. aethiopica Ethiopia, Kenya, Somalia Rock Hyrax  [21, 22] 
 
L. mexicana Central America, Mexico, TX Yucatan Deer Mouse, Tree 
rat, other rodents 
Mexico, 30.2%, 10.5%a, TX, 8 
casesa 
[23-28] 
 
L. amazonensis Brazil Various forest rodents 
(grass, pygmy mice) 
Brazil, 1 case [29, 30] 
 
L. tropica Mediterranean, Middle East, Western 
Asia, Indian subcontinent 
Human, foxes, golden 
jackals, hyrax, dogs 
Morocco, 8 cases [31-35] 
 
L. braziliensis Central, South America Forest mammals, marsupial 
species, opossum 
Mexico, 8.2%, 11.57%a, Brazil, 2-
3% 
[27, 28, 36-39] 
 
L. guyanensis Guyana, Suriname, northern Amazon 
basin 
Two-toed sloth, Forest 
mammals, marsupial 
species, opossum 
Colombia,  2.2% [40, 41] 
 L. peruviana Peru, Argentinean highlands Dog? Peru,  1.8%
b [42] 
 
L. shawi Brazil Cebus monkeys, sloths, 
pro-cyonids 
 [43] 
 L. lainsoni Brazil, Bolivia, Peru Lowland Paca, Rodents  [44] 
 L. naiffi Brazil, French Guyana, Ecuador, Perú Armadillos  [45] 
 L. venezuelensis Venezuela Unknown, cat? Venezuela, 6 cases
a [46] 
 
L. panamensis Panama, Costa Rica, Colombia Sloths, kinkajous, 
marsupial species, opossum 
Colombia, 12 cases, Panamá, 3.3%, 
Ecuador, 2 cases 
[47-51] 
Visceral 
Leishmaniasis 
L. donovani Indian subcontinent, northern and 
eastern China, Pakistan, Nepal, Eastern 
Africa, Sudan, Kenya 
Human, dogs, goats Sudan, 2 cases, Ethiopia, 14.8%, 
India, 6.5% 
[52-55] 
 
L. infantum (syn. 
chagasi) 
Middle East, Mediterranean basin, 
northern and northwestern China, 
northern and sub-Saharan Africa, 
Central and South America 
Dogs, foxes, jackals, 
wolves 
Mexico, 11.9%, 22.10%a, Brazil, 
7.14%-57%, Portugal,  4.3-25.2%, 
Spain,  8.1-13%, Italy, 2.6%, 
France,  4-8%, Greece,  2-30%, 
Uzbekistan , 32.1%, Turkey, 20.7%, 
China, 23.5-28.2%, Iran, 14.2%, 
10%ab, Jerusalem – 6.7%a 
Senegal, >40% 
[27, 28, 35, 37, 
56-83] 
a 
- Feline seroprevalence.  
b
 - Prevalence was measured from positivity on skin or splenic biopsy and culture.  
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Figure 1.2. The life cycle of Leishmania species. Sandflies inject infective promastigotes 
into a susceptible mammal during feeding. Promastigotes are phagocytised by resident 
phagocytes, transform into tissue-stage amastigotes, and multiply within these cells through 
simple division. The parasite continues to infect phagocytic cells either at the site of 
cutaneous infection or in secondary lymphoid organs, with eventual parasitemia. Sandflies 
become infected through feeding on a host either with an active skin lesion in CL or with 
parasitemia in VL. Parasites convert to promastigotes within the sandfly midgut. 
Promastigotes migrate from the midgut and transform into highly infectious metacyclic 
promastigotes. 
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Africa, and Asia. Occasionally cases of VL will arise from cutaneous disease-causing 
species, and occurred in United States troops due to infection with L. tropica [84]. VL arises 
from parasitic infection of phagocytic cells within secondary lymphatic organs (spleen, 
lymph nodes), liver, and bone marrow. Cutaneous forms of Leishmaniasis (CL) (Table 1.1) 
arise from infection of epidermal tissue after promastigote inoculation into the host.  In 
susceptible hosts and immunocompromised persons, disseminated cutaneous or diffuse 
cutaneous leishmaniasis may occur as a rare but severe manifestation CL.  A third form of 
the disease, Mucocutaneous Leishmaniasis (MCL), arises from a small percentage of 
cutaneous cases that cleared disease months or years prior to the onset of MCL.  MCL often 
begins with involvement of the nasal mucosa, including generalized inflammation and 
ulceration. Ulceration and necrosis of these areas may be severe, resulting in disfigurement 
and occasionally death. Mechanisms of mucocutaneous lesion formation are poorly 
understood, but a Leishmania RNA virus (LRV1), was associated with severe 
mucocutaneous lesions through a TLR3-dependent inflammatory response [85]. 
 Life cycles of Leishmania species are relatively simple involving mammalian hosts 
and vector stages (Figure 1.2).  Vectors for the various species of Leishmania are 
phlebotomine sandflies of the genus Lutzomyia in the Americas and Phlebotomus in other 
endemic regions.  The sandfly injects infective promastigotes into a susceptible mammal 
through its proboscis during feeding.  Promastigotes (Figure 1.3A) are quickly phagocytized 
by resident phagocytes, transform into tissue stage amastigotes, and survive and reproduce 
within these cells through simple division in a parasitophorous vacuole.  Depending upon 
host and parasite factors the parasite continues to infect phagocytic cells either at the site of 
cutaneous infection or in secondary lymphoid organs with eventual parasitemia (Figure 3B).  
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Sandflies subsequently become infected through feeding on a host either with an active skin 
lesion in CL or with parasitemia in VL.  Parasites convert back to metacyclic promastigotes  
 
 
 
Figure 1.3. Leishmania parasites in culture and in a tissue section. (A) Leishmania 
amazonensis promastigote from culture with a visible kinetoplast. (Photo by Pedro 
Martinez.) (B) Zoonotic visceral leishmaniasis in canine spleen. The spleen was enlarged and 
infiltrated by large numbers of foamy macrophages containing numerous intracellular 
Leishmania infantum amastigotes (arrows), confirmed by immunohistochemistry 
(magnification, ×100). 
 
 
 
within the sandfly midgut and reproduce to high numbers within 4-14 days. These 
promastigotes migrate from the midgut to the salivary glands where they await the initiation 
of feeding. 
 
CLINICAL LEISHMANIASIS
2 
Cutaneous leishmaniasis 
The disease categorization of leishmaniasis encompasses a spectrum of disease forms 
(cutaneous, mucocutaneous, visceral) and symptoms of varying severity [86, 87]. Cutaneous 
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lesions develop weeks to months after the sandfly bite, and are usually present on regions of 
the skin exposed to the sand fly bite [88]. Lesions are focal, and can be single, multiple or 
less commonly disseminated [89-91]. In non-endemic regions where CL is a less likely 
differential, repeated attempts at antibiotic or steroid therapy are unsuccessful. Lesions range 
grossly from small erythematous papules to nodules, scaly plaques, or ulcerated exudative 
lesions [89-91]. Regional lymphadenopathy is common in reaction to the migration of 
infected dendritic cells (DC) and macrophages to secondary lymphoid organs. Lesions are 
commonly self-limiting, with resultant depigmented scar [92]. Disseminated Cutaneous 
Leishmaniasis (DCL) is a rare presentation of CL, even in hyper-endemic regions, and is 
thought to be the result of host immunopathology in the form of a grossly inadequate Th1 
response [93-96]. Initial infection progresses much like uncomplicated CL, with subsequent 
progression to diffuse, non-ulcerated, macules, papules, and plaques. Due to the aberrant 
immune response during DCL, these lesions have extremely high numbers of amastigotes 
compared to typical CL lesions [95]. Generalized lymphadenopathy is common due to 
lymphatic spread of the Leishmania spp. amastigotes [95, 97].  
 
Mucocutaneous leishmaniasis 
Mucocutaneous leishmaniasis (ML), is typically more severe than CL and is not self-
limiting. ML is a known risk from Leishmania species of the Viannia (V) subgenus, typically 
found in Central and South America (L. (V.) braziliensis, Leishmania (V.) amazonensis, L. 
(V.) panamensis, and Leishmania (V.) guyanensis) [98, 99]. The pathogenesis of ML is not 
fully elucidated, but is associated with host immunopathology, similar to DCL, and parasite 
virulence. Recent research indicates a Leishmania RNA virus (LRV1) was associated with 
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severe mucocutaneous lesions through a TLR3-dependent inflammatory response [85]. MCL 
often begins with involvement of the nasal mucosa, including generalized inflammation and 
ulceration [86, 100]. Ulceration and necrosis of these areas may be severe, resulting in 
disfigurement and occasionally death.  Lesions arise on the nasal or oral mucocutaneous 
junctions, which may progress to other regions of the skin or oropharynx [100]. Nasal septal 
granulomas can be found with endoscopy or nasal biopsy [86, 100]. These lesions will 
progress to palatal ulcerations, with or without erythema and edema of the nares, nasal 
septum perforation, palatal ulceration, gingival edema, and periodontitis [101, 102]. 
Eventually, there is progressive destruction of the oronasopharyngeal mucosa, and 
cartilaginous facial and upper airway structures, resulting in disfiguration, secondary 
infection, and airway obstruction [92, 101, 102]. 
 
Visceral leishmaniasis 
 Visceral leishmaniasis (VL), caused by multiple species of Leishmania, is invariably 
fatal if left untreated [87]. The incubation period is variably and can range from a few weeks 
to years after exposure, depending upon the intensity of exposure and the immune 
competence of the patient. Onset is usually gradual with progressive weight loss, intermittent 
fever, pain, and weakness, although rapid onset VL with high fever can occur [103]. In 
symptomatic patients the spleen is large, firm, and palpable (splenomegaly), with or without 
hepatomegaly [103]. Lymphadenopathy is common with dissemination of amastigote- 
containing macrophages throughout the secondary lymphoreticular system. Hematologic 
abnormalities arise due to splenic and bone marrow infection, and result in ecchymoses, 
petechiae, extra-vascular hemolysis, and peripheral edema [103].  Clinical chemistry 
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abnormalities include anemia, thrombocytopenia, neutropenia, and pronounced 
hypergammaglobulinemia [103]. Circulating immune complexes are commonly associated 
with high levels of infection and hypergammaglobulinemia and can result in the formation of 
rheumatoid factors and glomerulonephritis in approximately 25-30% of human cases [104]. 
Co-morbidity with HIV infection can result in atypical presentation due to leukocyte 
depletion, in which disseminated infection to numerous tissues occurs in approximately 1/3 
of HIV/VL cases [101]. 
 
Canine leishmaniasis (CanL) 
Canine infection, primarily with Leishmania infantum, results in visceralizing disease with a 
similar, but not entirely overlapping presentation compared to human VL. The clinical 
presentation varies and includes dermal lesions, splenomegaly, generalized 
lymphadenopathy, cachexia, anorexia, muscle wasting, polyuria and polydipsia, 
keratoconjunctivitis, nail overgrowth, and hematologic abnormalities [105-107]. Splenic and 
hepatic lesions are similar to human VL with granulomatous splenitis characterized by large 
numbers of amastigote-infected macrophages, and lymphoplasmacytic and granulomatous 
portal and periportal hepatitis. Skin lesions are one of the most common presenting signs in 
endemic regions and can include non-pruritic dermatitis, ulcerative dermatitis, focal or 
multifocal nodular dermatitis, proliferative dermatitis, or mucocutaneous ulcerative or 
proliferative dermatitis [106, 108]. With these lesions, secondary bacterial pyoderma is the 
most common complicating co-morbidity. Histologically, these lesions are granulomatous or 
pyogranulomatous with acanthosis, orthokeratotic and hyperkeratotic hyperkeratosis, and 
ulceration with serocellular crust formation.  Lymphoplasmacytic vasculitis and peri-
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vasculitis may also be present. Renal disease is present to some degree, in nearly 100% of 
infected dogs, compared to 25-30% in humans [109, 110]. Lymphoplasmacytic and 
granulomatous interstitial nephritis is invariably present.  Glomerular alterations vary by 
symptomatic state of the animal and the degree of hypergammaglobulinemia, and can range 
from minimal change glomerulonephritis to mesangioproliferative and/or 
membranoproliferative glomerulonephritis, to glomerulosclerosis present in combination 
with the nephrotic syndrome [109, 110]. Ocular lesions may also occur in approximately 
16% of patients, depending on disease severity. Common manifestations are conjunctivitis, 
blepharitis, and anterior uveitis [107]. CanL is a disease similar in presentation and clinical 
signs to human infection, and naturally infected dogs are a representative pathologic and 
immunologic model of human VL. 
 
PATHOGENESIS
2 
Leishmania species have a unique pathogenesis and means of persistence within host 
cells enabling the establishment of long term chronic infection.  After a sand fly bite, an 
influx of both neutrophils and macrophages occurs, even in the absence of parasites [111]. At 
this stage the metacyclic Leishmania promastigotes are relatively immobile compared to 
other kinetoplast species [111]. Sand fly-derived salivary chemoattractants promote an influx 
of both neutrophils and macrophages at feeding site [111]. Infection of neutrophils, 
macrophages, and dendritic cells occurs at this stage of infection [111, 112]. Parasites inhibit 
phagosome acidification allowing survival within neutrophils, but have not been shown to 
transform into amastigotes or proliferate within neutrophils [113]. At the time of neutrophil 
apoptosis, surviving parasites are phagocytosed by resident and infiltrating macrophages, 
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where the parasites will transform into amastigotes, replicate, and establish long term 
infection.  The utilization of neutrophil apoptosis as a means of macrophage entry may be a 
unique evolutionary adaptation of the parasite for survival [111]. Dermal dendritic cells also 
become infected at the site of inoculation, becoming mature and migrating to regional lymph 
nodes.  This can be inhibited by pathogenic species L. amazonensis through enhanced ERK 
signaling from the phagosome resulting in improper dendritic cell maturation and decreased 
production of IL-12, a key pro-inflammatory mediator [114].  Leishmania phagocytosis is 
mediated through complement receptors1 (C1), 3 (C3), and mannose scavenger receptors, 
indicating both opsonization-dependent and independent mechanisms of invasion [115]. 
Uptake results in reorganization of F-actin and delayed phagolysosomal fusion [115, 116]. 
Leishmania are resistant to acidification as amastigotes, and persist in these compartments 
that are late endosome associated LAMP1, Rab7 positive vacuoles [117]. Amastigotes persist 
and replicate within the phagolysosome until eventual host cell lysis occurs. The ability of 
the parasite to direct phagosome trafficking and delay phagolysosome fusion is dependent 
upon surface lipophosphoglycans with differing side chains [117-119]. Leishmania species 
are also able to acquire nutrients needed for survival through the expression of LIT-1 to 
acquire Fe
2+
 needed for growth and survival [120].  
Leishmania utilize a number of immune evasion strategies to inhibit the immune 
response including the interruption of DC maturation as mentioned earlier, the stimulation of 
anti-inflammatory cytokines such as TGF- and IL-10, the interruption of cellular signaling 
of the STAT pathways necessary for IFN production, and through the induction of CD25+, 
FoxP3+ T regulatory cells. 
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PROTECTIVE IMMUNITY
2 
The immune response to all Leishmania species as an intracellular pathogen is 
dependent upon a timely and appropriate Th1 response including IL-12 production by 
dendritic cells and macrophages, efficient MHC II presentation, and subsequent 
IFNproduction from T cell populations.  In addition, cytokine secretion at the site of 
inoculation by keratinocytes may play an integral role in Th1 differentiation and parasite 
clearance including secretion of IL1, IL-6, IL-12, and IL-4 [121]. Innate immune system 
clearance of Leishmania is dependent primarily upon intra-cellular killing via superoxide and 
nitric oxide within phagolysosomes of infected macrophages, which is enhanced with IFN 
stimulation from NK cells early in infection and T cells at later stages. Neutrophils recruited 
to the inoculation site from the presence of sandfly saliva may be permissive to Leishmania 
growth, and the presence of neutrophils and of high levels of IL-17 have been associated with 
increased parasite load in CL, even amidst a robust cell mediated immune response [111, 
122]. While the correlates of protective immunity against Leishmania spp. are thought to be 
understood (high IFN, low IL-10 and low IL-4), the development of protective immunity 
through vaccination has proven challenging. For CL, leishmanization, skin inoculation with 
lesion exudate from infected patients in an inconspicuous area, is effective, providing long-
term immunity [123, 124]. However, this method can result in clinical disease as there are 
persistent parasites at the inoculation site [125, 126]. Whole-killed parasites have also been 
used, but their efficacy has been poor [127]. Second generation vaccines utilizing multiple 
immunogenic peptides in a fusion protein or genetically-modified, non-replicating 
Leishmania vaccines have demonstrated potential as vaccine platforms [128-133]. One of the 
only currently approved canine vaccines in Brazil, contains a fucose-mannose ligand of  L. 
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donovani with saponin adjuvant, with an approximate reduction in clinical disease by 60-
75% after 2 years [134, 135]. This vaccine does result in a high rate of adverse localized 
vaccine reactions. There are no currently approved human vaccines against any Leishmania 
species.  
 
EPIDEMIOLOGY AND TRANSMISSION DYNAMICS
1 
 Leishmania is endemic in 98 countries and 3 territories, with a high percentage of 
cases occurring in developing nations [136]. The distribution of competent vector species and 
leishmaniasis has expanded over the last decade, possibly due to an increasingly amenable 
environment of vector species, due to shifts in climate [137]. This results in approximately 
200-400,000 cases of VL and 700,000 to 1.2 million cases of CL each year  resulting in an 
estimated 20,000 to 40,000 deaths [136]. Greater than 90% of global VL cases occur in India, 
Bangladesh, Sudan, South Sudan, Ethiopia, and Brazil [136]. Among the 15 disease-causing 
species of Leishmania, 13 are thought to have some degree of zoonotic transmission, and in 
the case of L. infantum, dogs are the main reservoir, largely responsible for the transition 
from sylvatic to domestic transmission cycles [10, 56]. The multiple clinical forms of 
leishmaniasis will be discussed briefly in this review, primarily based on the degree of 
zoonotic transmission from companion animal species. 
 
Cutaneous leishmaniasis
 
 CL is caused by one of a number of Leishmania species with widespread distribution 
and includes a variety of location-specific reservoir species (Table 1).  In the old world 
Leishmania major is a widespread cause of CL.  The reservoirs for L. major vary by location 
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but include a number of species of rodents.  Population densities of these reservoirs and 
vectors are significantly tied to the seasonality of infection and increases in reservoir rodent 
population have been associated with numerous zoonotic cutaneous leishmaniasis (ZCL) 
outbreaks [56, 138].  L. aetheopica also causes ZCL and appears to be isolated to the 
highlands of Ethiopia. Reports have identified this species at lower altitudes as well, 
indicating that perhaps the distribution is more widespread, or that the area of endemicity is 
expanding [21].  CL caused by L. tropica is considered anthroponotic. However animal 
species can be infected and have been suggested as potential reservoirs, including the 
domestic dog (Table 1). 
 In the New World, numerous species of CL-causing Leishmania species are present, 
all of which have been identified in multiple mammalian species.  L. mexicana is found from 
Central America to the Yucatan peninsula in Mexico, and cases have been reported in Texas 
[23, 139-141]. There have been a number of isolated reports of companion animal cases that 
have not been travel associated in Texas [23, 139-141]. Notably, many of these cases of 
zoonotic CL were in cats [23, 139, 141], perhaps due to their more outdoor lifestyle. There 
have been 30 autochthonous cases of human CL in Texas through 2008, where CL is 
considered endemic [24]. While companion animal infection and transmission may occur, the 
predominant reservoir in Texas is considered to be the Southern Plains woodrat, Neotoma 
micropus [25]. There are vectors capable of dissemination of this species throughout the 
southern United States and it is likely that disease due to L. mexicana will increase in the 
United States over time [137]. 
 South American species of Leishmania causing CL, including L. amazonensis, L. 
brasiliensis, L. guyanensis, L. panamensis have sylvatic reservoirs. Two species causing CL 
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in South America are thought to have domestic animal reservoirs.  L. venezuelensis has been 
identified in several urban and peri-urban areas of Venezuela and it is suspected that the 
domestic reservoir species are infected cats [46]. L. peruvianasis, a species once limited to 
altitudes of 1200-3000 meters in the Peruvian Andes, uses the dog as a primary reservoir 
although limited evidence of canine transmission to sand flies exists [42]. In all, there exists a 
potential for zoonotic transmission of cutaneous leishmaniasis from companion animals, 
most notably the dog.  While there are numerous reports of canine and feline infection and 
clinical disease with ZCL, their role as a reservoir has not been definitively established. 
 Human risk factors for ZCL primarily are dependent upon exposure to the various 
vector species, and the presence of populations of appropriate reservoir species.  In all cases, 
urbanization and encroachment on wilderness areas has resulted in increased interaction 
between human, reservoir and vector species, and establishment of urban domestic life cycles 
rather than sylvatic cycles.  The establishment of urban domestic transmission cycles holds 
the potential for larger outbreaks of ZCL due to the spread between naïve human hosts 
during everyday life versus occasional infection due to human introduction into the sylvatic 
cycle. Deforestation and agricultural development including damming of water and irrigation 
also create new environments with food sources optimal for the survival of reservoir rodent 
species. An outbreak in Mazar-e Sharif in northern Afghanistan was traced to exploding 
population of Rattus opimus in an area of irrigation canal construction [138]. L. guyaenensis 
in Brazil developed urbanized lifecycles within Brazil and increased risk of infection 
dependent upon household distance from the forest [142, 143]. Interestingly, long-term 
surveillance in Bahia, Brazil suggests that the number of cases in agricultural workers has 
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decreased in the last 20 years, with an overall increase in disseminated disease, and in coastal 
areas [144]. 
 Recent studies have identified being younger in age (5-19), sleeping without bed nets, 
ownership of dogs and cattle, and the presence of organic animal material as associated with 
a higher risk of infection.[145].  Additionally social factors such as low education and 
income increase the likelihood of exposure due to poor housing and environments conducive 
to vector presence.  These include having mud-walled housing (not brick or concrete), having 
dirt streets and/or floors, and cleanliness of the domestic environment, and working in 
forested areas [146-148].  
 
Zoonotic Visceral Leishmaniasis (ZVL)
1 
 Visceral leishmaniasis is caused by Leishmania donovani in India, areas of Asia, 
Sudan, South Sudan, Kenya, and Ethiopia, and by Leishmania infantum (syn. L. chagasi) 
throughout South America, in areas of Central America and Mexico, the Mediterranean 
basin, Middle East, central and southwestern Asia, northwestern China, and northern and 
sub-Saharan Africa. Transmission of L. donovani is considered solely anthroponotic, 
although animal infections have been reported, and reservoir status has been suggested for 
dogs in Sudan and for goats and possibly other species in Nepal [52, 53]. 
 Zoonotic infection with L. infantum is responsible for the majority of zoonoses-based 
human cases of VL.  As with other species of this genus, the vectors for Leishmania in the 
New World are Lutzomyia species, predominantly Lutzomyia longipalpis, and in the Old 
World are a number of species from the genus Phlebotomus. Canids are considered both the 
primary sylvatic and domestic reservoir, with foxes, jackals, and wolves filling the role of 
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sylvatic reservoirs and the domestic dog serving as the domestic reservoir [10, 56]. There is 
also data suggesting that wild felids can be susceptible to infection, although their definitive 
role in transmission is unclear [149]. Similarly, domestic cats in endemic areas of Brazil can 
be infected and could pose as potential secondary reservoirs [57]. Humans are relatively 
resistant to L. infantum and have a high rate of asymptomatic infection. The WHO estimated 
200,000-400,000 clinical VL cases to be a gross underestimate of the burden of human 
L.infantum infection worldwide [150]. If a patient has immunologic control of L. infantum 
infection, low or absent parasitemia and compartmentalization of the parasite within the 
secondary lymphoid organs and bone marrow may reduce the likelihood of transmission to 
sand flies.  When ZVL occurs in immunocompromised persons or animals, parasite load 
increases and transmission, as well as clinical disease, is likely to occur. 
 The role of the domestic dog in maintenance and transmission of L. infantum is clear.  
In Brazil, infected dogs in urban and peri-urban endemic areas are common, accompanied by 
a sufficient environment for L. longipalpis [58].  Vertical transmission has been documented 
in the dog, suggesting a vector-independent means of transmission [151]. In northeastern 
Brazil, there was a reported seroprevalence rate of 32.5%, with parasitemia in almost 47% of 
seropositive dogs [58]. In southeastern Brazil, seroprevalence rates in dogs ranged between 
15.9% in urban areas and up to 57% in endemic rural areas [59, 60]. In endemic 
Mediterranean areas canine seropositivity ranged from approximately 8.1% in central Spain, 
13% in southern Spain, and between 4 and 25% in Portugal, France, Italy, Greece, Cyprus, 
and Turkey [62, 152, 153]. The presence of these animals was significantly correlated to 
human risk, but incidence of human disease varied by country and region [154]. In Europe 
the estimated incidence rate of human ZVL ranges from 0.02-0.47 per 100,000 except in 
18 
 
 
Turkey where a higher 1.6-8.53 cases/100,000 people was reported [58, 59, 61, 155, 156]. In 
endemic areas of Brazil the incidence of VL was much higher with twice the number of cases 
of the entire Mediterranean region from 2004—2008 [58, 59].  
 Risk factors for ZVL in large part relate directly to the differences in incidence of 
human disease in Brazil and Europe.  Numerous studies have demonstrated risk for ZVL 
based on the presence of dogs within the household, the housing type (comparing mud-
walled housing to concrete or brick housing), education level, income, and disease 
knowledge [157]. Clinical ZVL has also been associated with poorer nutrition [157]. Many 
of the same factors associated for human ZVL also apply to owner characteristics associated 
with risk for canine VL [158]. Vertical transmission has been characterized in the dog and 
suggested in humans causing an increased risk of infants born to parasitemic mothers [159]. 
Treatment of pregnant women with liposomal amphotericin B appears to be successful in 
reducing the occurrence of congenital VL [160]. Additional risk factors for humans are 
related to their immunologic status and ability to clear infection or maintain an asymptomatic 
state. These include concurrent infection with HIV, co-infections with helminth parasites, 
drug abuse, and suppression of the immune system for any reason. These co-morbidities, 
especially HIV co-infection, confer a higher risk of the development of ZVL [158]. The risks 
for dogs also include co-infection with other parasites, rickettsial diseases, heartworm 
disease, or immune suppression [160, 161]. Genetic susceptibility may also be a factor for 
the development of clinical disease. Large scale studies conducted in numerous countries 
have indicated a role for genetic susceptibility including polymorphisms of a number of 
metabolic genes, iron metabolism genes, chemokines and cytokines, and HLA alleles [162]. 
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This suggests a complex evolutionary interplay of parasite and host factors, which are likely 
associated with disease susceptibility. 
 
PREVENTION 
 Prevention of Leishmaniasis requires blocking a step in the parasite’s life cycle.  
Interrupting sandfly transmission is of primary importance for individual and community 
protection from CL and VL.  Avoiding being outside during times of sandfly feeding, 
typically from dusk until dawn, can greatly reduce transmission. Wearing topical insect 
repellents and utilizing permethrin treated bed nets or clothes are also effective in repelling 
sand flies [163-165].  In domestic areas residual household sprays have been utilized to 
reduce the presence of the vector, but inconsistent compliance with periodic spraying, cost, 
and concerns over insecticide resistance limit the efficacy of this type of intervention on a 
widespread, long-term basis.  
 Approaches to address reservoir populations have also been implemented in an 
attempt to reduce ZVL. Brazil has implemented public health policy utilizing voluntary 
surveillance and culling of positive dogs to reduce the burden of VL [158]. While studies 
have shown that vigilant surveillance and culling can reduce the canine prevalence of VL to a 
degree, impacts on human infection are more difficult to ascertain [159].  Limitations in 
diagnostic sensitivity likely leads to false-negative diagnosis in a large number of 
asymptomatic dogs, delays between testing and dog removal increase the likelihood of 
transmission, and the financial and emotional cost of the implemented policy in Brazil is high 
[61, 159, 166].  The use of permethrin or deltamethrin collars or topical applications have 
shown efficacy in reducing sandfly feeding and transmission in endemic areas [167, 168]. 
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However, the cost and necessity for reapplication make these interventions more difficult to 
utilize in many endemic regions.  Limiting the degree of human infection is also important 
for control and prevention of severe clinical disease.  Public health efforts have resulted in a 
reduction of severe cases in Brazil. There is currently no vaccine for human leishmaniasis. 
Continued research may result in a vaccine with long-term, efficacious, protection. 
 
THESIS OVERVIEW AND PROJECT OBJECTIVES 
 Leishmaniasis afflicts between 1.5 and 2 million people across the world annually, 
and is endemic in 98 countries and 3 territories [136, 137]. The number of asymptomatic 
infections with Leishmania infantum, a causative agent of visceral leishmaniasis, is high 
compared to symptomatic disease. In one Brazilian study, exposure measured by the 
Montenegro skin test (a delayed type hypersensitivity skin test) was 71.3% compared to 
9.7% positive via ELISA [169]. Seroconversion is often associated with progression toward 
symptomatic VL. This indicates a high number of asymptomatic infections compared to 
individuals progressing toward clinical disease. The mechanisms that lead to the precipitation 
of symptomatic VL are poorly understood. Furthermore, symptomatic Leishmania infections 
are associated with immune pathology, including alterations in T cell function, in 
macrophage phenotype and function, and in B cell responses [170, 171]. The B cell response 
during chronic VL becomes pathologic, driving a hypergammaglobulinemia and subsequent 
immune complex deposition in tissues such as the renal glomerulus [106]. This occurs in 
nearly 100% of dogs with VL and in approximately 25-30% of human VL patients [104, 
106]. Developing effective means of prevention or immunotherapy during Leishmania 
infection has proven difficult. Vaccination platforms for VL in humans and dogs have thus 
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far been ineffective or have a high rate of adverse events, paired with efficacy measured as a 
prevention of clinical disease, and not necessarily of transmission capability [127]. Natural 
canine infection with Leishmania infantum is pathologically and immunologically similar to 
human VL caused by the same pathogen, and is also of direct public health importance as the 
main domestic reservoir for human infection. 
 The objectives of this thesis were characterize natural Leishmania infantum infection 
in the dog as 1) an immunologic and pathologic model of human VL, 2) as a model of 
immune complex-mediated glomerular disease, and 3) to directly address prevention of 
CanL. The results generated by the research in this thesis contribute significantly to the 
understanding of mechanisms leading to the onset of clinical VL, through a novel description 
of T cell exhaustion during symptomatic VL, mediated through a gradual increase in 
coinhibitory surface receptor Programmed Death 1 (PD-1). This T cell exhaustion results in 
impaired macrophage production of reactive oxygen species (ROS), and impaired reduction 
of Leishmania infantum in PBMC ex vivo. The second section of this thesis contains, to our 
knowledge the first description of alterations in glomerular autophagy and inflammasome 
activation associated with immune-complex mediated glomerulonephritis severity in any 
species. This research will contribute to knowledge of the glomerular response to immune 
complex deposition, and elucidate potential avenues of intervention to limit long-term 
chronic renal damage. The third section of this thesis will describe the immunogenicity of 
one of a handful of second generation CanL vaccines, in multiple platforms, to determine the 
optimal means of administration. This research may lead, in part, to the approval of a novel 
polypeptide CanL vaccine, resulting in improved prevention of CanL and subsequent human 
transmission. This research as a whole is a significant contribution to the understanding of 
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the pathogenesis, immune response, and prevention of CanL and as a model of human 
infection. A comprehensive understanding of the basic mechanisms of VL immunity and 
pathology in a representative model is the optimal means of developing prevention and 
therapy for human leishmaniasis. 
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ABSTRACT 
There is currently no licensed vaccine for visceral leishmaniasis (VL), and 
chemotherapy has thus far had frequent toxicity, with a high rate of VL recrudescence. 
Control of Leishmania infantum infection is dependent upon Th1 CD4+ T cells to promote 
macrophage intracellular clearance of parasites. Deficient CD4+ T cell effector responses 
during clinical visceral leishmaniasis (VL) are associated with elevated production of IL-10, 
TGF-, and IL-4. In a naturally occurring canine model of VL, we characterized occurrence 
of CD4+ and CD8+ T cell exhaustion as a significant stepwise loss of antigen-specific 
proliferation and IFN production, corresponding to increasing VL symptomatology. 
Exhaustion was associated with a four-fold increase in the population of T cells with surface 
expression of Programmed Death 1 (PD-1) between control and symptomatic populations. 
Exhausted populations of CD8+ T cells, and to a lesser extent CD4+ T cells, were present 
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prior to the onset of clinical VL. Exhausted T cells did not undergo significant apoptosis ex 
vivo with antigen stimulation, even with recovery of proliferation. Antibody block of PD-1 
ligand, B7.H1, promoted return of CD4+ and CD8+ T cell function and dramatically 
increased reactive oxygen species production in co-cultured monocyte-derived phagocytes.  
As a result, these phagocytes had decreased parasite load.  These results demonstrate that 
PD-1-mediated exhaustion during VL influences macrophage reactive oxygen intermediate 
production and improves the ability of phagocytes to clear parasites from cells isolated from 
animals with natural infection. Influencing PD-1/B7.H1-mediated negative regulation of the 
CD4+ Th1 response has potential to significantly improve therapeutic outcomes for visceral 
leishmaniasis, limiting immune pathology, and slowing the onset of symptomatic disease. 
 
INTRODUCTION 
 Zoonotic visceral leishmaniasis (VL) is a fatal systemic illness, resulting in 500,000 
annual new human cases and approximately 50,000 deaths per year. Leishmania infantum, a 
vector-borne, protozoan parasite, is the causative agent of VL in the New World.  Natural 
hosts of L. infantum include dogs and humans [1]. Asymptomatic status depends on a T 
helper 1 protective response during chronic VL. In patients that progress to disease, the 
immune response was skewed toward TGF-, IL-10 or IL-4-producing Th2 and/or T 
regulatory cells [2, 3]. We previously demonstrated that as dogs progressed to clinical VL, 
there was impaired CD4+ T cell proliferation and IFN production ex-vivo in response to L. 
infantum antigen with increased production of IL-10, similar to human VL [4]. T cell 
exhaustion has been defined as antigen-specific effector T cell dysfunction characterized by 
sustained expression of inhibitory receptors including PD-1 and decreased effector cytokine 
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production [5]. Exhaustion of CD8+ T cells has been identified in chronic viral infections and 
parasitic disease including toxoplasmosis and cutaneous leishmaniasis [6-8]. Here we report, 
for the first time, concurrent CD4+ and CD8+ T cell exhaustion in VL. This exhaustion was 
mediated by PD-1 surface expression on CD4+ and CD8+ T cells, associated with 
progressive disease.   
 T cell exhaustion progresses incrementally, and can eventually result in the clonal 
deletion of CD8+ T cells during chronic viral infection [9]. Reports of chronic infection 
indicate that populations of exhausted T cells are maintained by TCR stimulation with 
cognate antigen, even in the absence of IL-7 and IL-15, with low levels of proliferation [10]. 
Additional studies during experimental Leishmania major infection indicate that antigen-
experienced T cells preferentially respond to presented antigen to the exclusion of naïve T 
cell populations [11]. Research into T cell homeostasis utilizing adoptively transferred 
ovalbumin (OVA)-specific CD4+ T cells into OVA transgenic mice with continual antigen 
exposure demonstrate a population of tolerant T cells that survive a contraction phase and are 
quiescent but can maintain tolerance in the absence of clonal deletion [12]. In this study we 
evaluated apoptosis in CD4+ and CD8+ T cells from asymptomatic and symptomatic dogs 
infected with Leishmania infantum, demonstrating the presence of an exhausted T cell 
population which does not proliferate or undergo apoptosis in response to antigen. The CD4+ 
and CD8+ populations were responsive to blockage of PD-1/B7.H1, increasing proliferative 
capacity, indicating that this effector memory population had not been clonally deleted. 
Previous reports demonstrated that phagocyte-based reactive oxygen (ROI) and 
nitrogen intermediates (RNI) were critical for removal of intracellular Leishmania [13, 14]. 
Production of ROI and RNI required T cell IFN-production [15]. In this study, blockade of 
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B7.H1 resulted in recovery of Th1-effector function, recovery of phagocyte superoxide 
production and decreased parasite load in peripheral blood-derived monocytes from 
naturally-infected dogs. These novel findings link rescue from CD4+ T cell exhaustion to 
improved monocyte function through augmented of superoxide production and removal of 
intracellular L. infantum. 
 
MATERIALS AND METHODS 
Sample Population and Study Enrollment – Dogs were enrolled by serology, clinical signs, 
and quantitative Real Time-PCR (qRT-PCR) positivity as previously described [4]. Dogs 
were 2 to 7 years old, and had complete veterinary care. Twenty milliliters of blood was 
collected from each dog at intervals greater than 2 weeks. Procedures were performed with 
approval from Iowa State University IACUC. 
 
Clinical Staging of Study Animals - Study animals were assessed via physical and laboratory 
examination and L. infantum diagnostics (L. infantum kinetoplast DNA (kDNA)-specific 
qPCR, IFAT, and K39/22 (DPP, Chembio, Medford, NY) serologic analysis). Infected 
animals were classified as: 1) asymptomatic- no clinical signs, qPCR positive, and IFAT 
<1:256, 2) symptomatic- two or more signs of leishmaniasis (lymphadenomegaly, palpable 
liver or spleen, alterations in hepatic or renal enzymes), IFAT ≥ 1:256, and qPCR positive.  
 
Sample Handling and PBMC Isolation - Whole blood samples were separated into PBMC as 
previously described [4]. Whole blood samples collected in heparin-containing tubes were 
diluted 1:1 with 1x Hank’s Buffered Salt Solution (Cellgro, Manassas, VA) and 25mM 
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HEPES .  Diluted whole blood was centrifuged at 800 rcf (Eppendorf, Hauppauge, NY) for 
30 minutes at room temperature through Ficoll/Histopaque 1077 (Sigma Aldrich, St. Louis, 
MO) as previously described [4].  PBMC were counted with an automated cell counter 
(Beckman Coulter, Brea, CA).  PBMC were washed twice in phosphate-buffered saline 
(PBS) and suspended in complete medium (CTCM) (RPMI 1640 supplemented with 10% 
fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM l-glutamine, and 25 
mM HEPES buffer). PMBC were counted and adjusted to 4 × 106/ml for further analysis. 
Cells were then split for evaluation of proliferation and intracellular staining for flow 
cytometry, or for qRT-PCR, nitro-blue tetrazolium assay (NBT) (Sigma Aldrich, St. Louis, 
MO), or ELISPOT Assays. 
 
Preparation of parasites - L. infantum (LIVT-2) grown for use as positive control for kqRT-
PCR or freeze-thawed L. infantum antigen (f-t L.i.), prepared as previously described, frozen 
in liquid nitrogen with subsequent thaw at 37oC for 3 cycles, and stored at -80oC [4]. 
Leishmania infantum (LIVT-2) was grown in complete Grace's medium (incomplete Grace's 
supplemented with 20% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 2 mM l-glutamine). Parasites were harvested, pelleted at 2500 x g for 15 min at 4°C, 
washed twice with phosphate-buffered salt solution (PBS), and suspended in PBS to a 
concentration of 10
7
 parasites/ml. Ten 1:5 serial dilutions were made and 50 µL of each 
dilution was spiked into 150 µL of negative canine blood.  
 
Antigen stimulation -   Cells were stimulated with Concanavalin A (ConA; 5 μg/ml) for 4 
days and f-t L.i. (10 μg/ml) for 7 days as previously described [4]. Asymptomatic dog PBMC 
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were stimulated with distemper virus vaccine (Pfizer, Kalamazoo, MI) as a Non-Leishmania, 
antigen Specific Control (NSC) for 10 days.  24 hours prior to cell harvest, 5-ethynyl-2´-
deoxyuridine (EdU) (Invitrogen, Grand Island, NY) was added at 10 M, and 10 g/ml 
brefeldin A (Sigma, St. Louis, MO) was added 6 hours before harvest. Cells were harvested 
and washed prior to surface and intracellular labeling. 
 
IL-10 and B7.H1 block - Non-adherent PBMC were removed and saved in separate culture.  
Adherent cell populations were CD3
- 
CD11b
+ 
by flow cytometry (data not shown). Adherent 
cells were treated with 10 g/ml anti-B7.H1 antibody (eBioscience, San Diego, CA) or 
isotype for 4 hours, washed, and non-adherent cells were returned to culture for antigen-
stimulation. This blocked adherent cell B7.H1 specifically. IL-10 block was performed via 10 
g/ml anti-canine IL-10 antibody (R and D Systems, Minneapolis, MN). 
 
PBMC immunolabeling – PBMC were labeled similarly to [4], with the following PBMC 
labeling panel: Canine PBMC labeling panel: EdU Click-It (Invitrogen, Grand Island, NY), 
anti-canine CD4/Alexafluor 647 (AbD Serotec, Raleigh, NC), anti-canine CD8/Alexafluor 
700 (AbD Serotec, Raleigh, NC), anti-canine IFN/Zenon R-PE (R&D systems, Minneapolis, 
MN)(Invitrogen, Grand Island, NY), anti-canine IL-10/Zenon APC/Alexafluor 750 (R&D 
systems, Minneapolis, MN)(Invitrogen, Grand Island, NY), and anti-human biotinylated PD-
1/PE-Cy7 streptavidin (R&D systems, Minneapolis, MN) (eBioscience, San Diego, CA). 
Cells blocked with 25 l of canine serum, with mouse and rat non-specific polyclonal IgG at 
20 g/106 PBMC for 20 minutes at 4oC. Cells were blocked for 20 minutes, 4oC, 
permeabilized with saponin reagent (Invitrogen, Grand Island, NY) and preserved in BD 
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stabilizing fixative (BD biosciences, San Jose, CA).  Samples were analyzed within 48 hours. 
Data acquired via FACScanto (BD biosciences, San Jose, CA) with FlowJo analysis 
(TreeStar Inc., Ashland, OR). 
 
ELISpot - PBMC were stimulated as previous and incubated on anti-canine IFN or IL-10 
capture antibody coated plates (R&D systems, Minneapolis, MN). 100 l of 0.5 g/ml 
biotinylated detection antibody (R&D systems, Minneapolis, MN) was added. Spots counted 
as average of duplicate wells over 4 dilutions, standardized to spots per 106 PBMC. 
 
IL-10 ELISA - Supernatants from unlabeled PMBC (2 × 105) were collected at indicated time 
points and stored at −20°C until analysis. IL-10 production was measured via ELISA (R&D 
Systems, Minneapolis, MN) per manufacturer's recommendations. 
 
Nitric oxide production – The concentration of nitrite was assessed by the Griess reaction, in 
which 50 µl cell culture supernatant and Griess reagent (LabChem, Pittsburgh, PA) was 
mixed and incubated at RT. The absorbance was measured at 550nm via microplate reader 
(Molecular Devices, Sunnyvale, CA).  Nitrite concentration determined via a sodium nitrite 
standard curve.  
 
Superoxide production - Production of superoxide was assessed using Nitro Blue Tetrazolium 
(NBT) (Sigma Aldrich, St. Louis, MO) tablets. NBT tablets were dissolved in 1ml water, 30 
µl added to cells, and incubated for 60-90 minutes. Coverslips were harvested, fixed, and 
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stained with eosin. Cells were counted as percent cells containing formazan precipitate. All 
evaluations were based on average of 600 cells per experiment with blinding. 
 
Polymerase chain reaction assay - DNA was isolated and RT-PCR performed as previously 
described (12). DNA was isolated using the Qiagen blood DNA isolation kit (Qiagen, 
Valencia, CA) according to the manufacturer's instructions. DNA quality and quantity were 
measured using a NanoDrop ND1000 spectrophotometer (Nanodrop, Wilmington, 
DE). Leishmania SSU rRNA specific fluorogenic probe (5′-6-carboxyfluorescein  
[6-FAM]-CGGTTCGGTGTGTGGCGCC-3′) and its flanking primers (F, 5′-
AAGTGCTTTCCCATCGCAACT-3’; R, 5′-CGCACTAAACCCCTCCAA-3’ (Applied 
Biosystems, Foster City, CA) previously designed (Wortman et al. 2001) were used. Blood 
DNA samples were assayed via qPCR in duplicates of two dilutions (straight, 1:10) using a 
Stratagene Mx3005P qPCR system (Agilent, Santa Clara, CA) via a 96-well format and  
perfeCta qPCR SuperMix, Low ROX master mix (Quanta Biosciences, Gaithersburg, MD). 
Primers were used at 775 nM and probe at 150 nM, with thermocyling at 95°C for 3 min and 
50 cycles of 95°C for 15 s, 60°C for 1 min. Results were analyzed via MxPro QPCR software 
version 4.01, Microsoft Excel, and GraphPad Prism version 5.04 (GraphPad Software, La 
Jolla, CA). 
 
Statistical analysis – Statistical analysis was conducted with pair-wise Student’s t-tests or one 
way ANOVA with a Tukey’s post-test via Graph Pad Prism version 5.04 (GraphPad 
Software, La Jolla, CA), significance at =0.05. qRT-PCR data was log-transformed for one-
way ANOVA analysis. Graphical data presented as arithmetic mean + SEM. 
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Figure 2.1. Leishmania infantum infection promotes progressive CD4+ T cell 
exhaustion. PBMC from L. infantum -infected dogs were stimulated with f-t L. infantum, or 
a non-mitogen antigen-specific positive control (NSC) (A-C) - CD4+ T cell plots of negative 
control (left), asymptomatic (middle), and symptomatic (right) dog PBMC for (A) CD4+ 
proliferation via EdU incorporation, (B) CD4
+
 IFN, and (C) CD4+ IL-10+, vs. PD-1+ in 
response to f-t L.i. (D-G) - Population graphs of  CD4
+
 T cell (D) PD-1 surface expression, 
(E) proliferation measured via EdU incorporation, (F) IFN expression, and (G) IL-10 from 
NSC-stimulated, asymptomatic and symptomatic animals. (H) Peripheral blood parasite 
levels in asymptomatic and symptomatic dogs measured by qPCR, expressed as log number 
of parasites. All experiments included n>21 dogs, 10 asymptomatic dogs for NSC. *p<0.05, 
**p<0.01 via one-way ANOVA with Tukey’s post-test (A-G), or un-paired Student’s-test 
(H). 
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RESULTS 
CD4+ T cells from animals with visceral leishmaniasis displayed an exhausted phenotype. 
Alteration in CD4+ effector function during VL is well established, with 
demonstrated involvement of IL-10, IL-4, TGF, and cells able to produce both IL-10 and 
IFN [2, 3]. We previously demonstrated these alterations in L. infantum-infected dogs as 
they progress to symptomatic VL [4]. These findings were suggestive of an exhausted 
phenotype. We obtained PBMC from dogs naturally infected with L. infantum and stimulated 
these cells with media, freeze-thawed L. infantum (f-t L.i.), Concanavalin A, or Canine 
Distemper antigen (Non-Leishmania Specific antigen Control) (NSC) to evaluate whether the 
phenotype of CD4+ and CD8+ T cells from dogs with asymptomatic and symptomatic VL 
infection was consistent with functional T cell exhaustion.  
Population surface expression of PD-1 on CD4+ T cells was significantly increased in 
asymptomatic (two-fold) and symptomatic (four-fold) L. infantum-infected animals (Figure 
2.1), as compared to expression on cells from asymptomatic dogs stimulated with a non-
Leishmania antigen (NSC) ex vivo (Figure 2.1D). The percent of CD4
+
 T cells capable of 
proliferation in response to f-t L.i. antigen was significantly reduced in animals with 
symptomatic VL, with five-fold reduction compared to asymptoamtic NSC and 
asymptomatic animals (Figure 2.1A, E). Intracellular staining revealed a 67% reduction in 
the percentage of CD4
+
 cells responding to f-t L.i. stimulation by IFN production 
compared to either NSC or asymptomatic animals (Figure 2.1B, F). Consistent with previous 
studies of leishmaniasis [2] and of T cell exhaustion [16, 17], the percentage of IL-10+ CD4+ 
T cells in f-t L.i.-stimulated PMBC from symptomatic animals increased almost six-fold and 
over two-fold compared to NSC and asymptomatic animals respectively (Figure 2.1C, G).  
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Figure 2.2. Leishmania infantum infection promotes progressive CD8+ T cell 
exhaustion. PBMC from L. infantum-infected dogs were stimulated with f-t L. infantum, or a 
non-mitogen antigen-specific positive control (NSC) (A-D) - Population graphs of  CD8
+
 T 
cell (A) PD-1 surface expression, (B) proliferation measured via EdU incorporation, (C) 
IFN expression, and (D) IL-10 from NSC-stimulated, asymptomatic and symptomatic 
animals. All experiments included n>16 dogs, 17 dogs for NSC. *p<0.05 compared to NSC, 
**p<0.01 compared to all experimental groups via one-way ANOVA with Tukey’s post-test 
(A-D). 
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We substantiated the alterations in IFN and IL-10 intracellular production via ELISpot after 
16 hours in culture with media, f-t L.i., or NSC (Supplemental Figure 2.1A, B).  ELISpot and 
IL-10 ELISA demonstrated significant reductions in PBMC IFN production (Supplemental 
Figure 2.1A) and significant elevations in PBMC IL-10 production both in asymptomatic and 
symptomatic animals (Supplemental Figure 1B). Functional exhaustion and symptomatic VL 
was also associated with a significant increase in L. infantum burden within PBMC (Figure 
2.1, H). The lack of antigen-specific CD4+ effector responses from these cells indicates the 
presence of CD4+ T cell exhaustion during VL, associated with increasing peripheral 
parasite load.   
 
CD8+ T cells from asymptomatic and symptomatic VL animals displayed characteristics of 
exhaustion. 
 CD8+ T cell exhaustion has been previously characterized during numerous chronic 
viral infections, protozoal infections, and cutaneous leishmaniasis [6, 7, 9]. Pro-inflammatory 
cytokines, including IFN, are produced primarily by both CD4+ and CD8+ T cells during 
chronic VL [18]. The presentation of intracytoplasmic L. infantum antigen on MHC class I 
has been previously shown to be important for the immune response during leishmaniasis, 
although the mechanism is incompletely understood [19]. CD8+ T cell exhaustion has not 
been previously reported during naturally-occurring VL, and the relationship of CD4+ to 
CD8+ T cell exhaustion during VL progression is not known. We evaluated characteristics of 
exhaustion in CD8+ T cells from the peripheral blood of asymptomatic and symptomatic 
dogs infected with Leishmania infantum, after ex vivo stimulation with media, freeze-thawed 
L. infantum (f-t L.i.), concanavalin A (ConA), or canine distemper antigen (NSC).   
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 Surface expression of PD-1 was significantly elevated in CD8+ T cells from animals 
with asymptomatic (1.5 fold increase) and symptomatic VL (two-fold increase) as compared 
to NSC (Figure 2.2A). Mean surface expression of PD-1 on CD8+ and CD4+ T cells from 
VL symptomatic animals was similar with means of 38.69 and 36.84 respectively (Figure 
2.1D, 2.2A). However, during asymptomatic infection, the extent of CD8+ exhaustion was 
greater than in the CD4+ T cell population, with a higher number of dogs with significant 
impairment in CD8+ T cells during asymptomatic infection than in CD4+ T cells and 
elevated expression of PD-1 (Figure 2.2A, 1D). VL symptomatic animals had significant 
five-fold reduction in proliferative capacity (Figure 2.2B), and three-fold reduction in the 
capacity of CD8+ T cells to produce IFN(Figure 2.2C) in response to whole f-t L.i. 
compared either to NSC or asymptomatic animals. There was no significant change in 
intracellular IL-10 production. This data indicates the presence of pan-T cell exhaustion 
during symptomatic VL, and a large percentage (>40%) of asymptomatic animals with 
phenotypic CD8+ T cell exhaustion and elevated PD-1 (Figure 2.2A, B, C). T cell exhaustion 
during VL was associated with elevated expression of inhibitory receptor PD-1 and could 
potentially be identified prior to the onset of symptomatic disease.  This exhaustion was 
associated with clinical progression of VL and could be a predominant contributing factor to 
the onset of symptomatic VL. 
 
T cell exhaustion in CD4+ T cells from symptomatic VL animals is reversed by B7.H1 block. 
An increased percentage of PD-1 expressing CD4+ T cells was progressively 
associated with CD4
+
 T exhaustion during symptomatic VL. Previous studies utilizing B7.H1 
antibody block demonstrated recovery of CD8+ T cell effector function [16, 20]. Our  
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Figure 2.3.  PD-1/B7.H1 interaction necessary for CD4+ T cell exhaustion during 
symptomatic VL.  Adherent PBMC treated with B7.H1 blocking antibody or IL-10 blocking 
antibody. PBMC stimulated as previous. (A) CD4+ cellular proliferation (top row) and CD4+ 
T cell IFN (bottom row), compared to PD-1 (x-axis) in PBMC from negative control (left), 
asymptomatic VL (middle), and symptomatic VL (right) dogs, with isotype control (left), 
anti-IL-10 antibody (center), or anti-B7.H1 antibody treatment (right). (B) CD4+ cellular 
proliferation, n=15. (C) CD4+ PBMC IFNintracellular production, n=21. (D) Production of 
IL-10 via ELISA, n=11. **p<0.01, via one way ANOVA with Tukey’s post-test. 
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previous studies demonstrated an increased percentage of IL-10-producing CD4+ T cells and 
increased IL-10 production during symptomatic VL. Others have postulated that IL-10 may 
induce CD4+ T cell suppression during chronic VL [2, 21]. Based on this, our hypothesis 
was that IL-10/IL-10R and/or PD-1/PDL-1 (B7.H1) signaling is necessary for CD4+ T cell 
exhaustion in PBMC from symptomatic VL animals. Block of B7.H1 resulted in significant 
recovery in the population of CD4+ T cells able to proliferate to f-t L.i. both in asymptomatic 
and symptomatic infection-derived PBMC (Figure 2.3 A, B). A lesser magnitude of recovery 
was associated with greater severity of clinical disease and more extensive T cell exhaustion 
(Figure 2.3 and data not shown). The IL-10 block trended toward increased proliferation-
capable CD4+ T cells in PBMC from both asymptomatic and symptomatic animals and was 
not statistically significant (Figure 2.3). B7.H1 block resulted in significant recovery of a 
population of CD4
+
 IFNcells compared to isotype or IL-10 antibody-treated PBMC from 
symptomatic animals and compared to isotype-treated PBMC from asymptomatic animals 
(Figure 2.3A, C). The number of IFN-producing PBMC was also significantly increased 
after B7.H1 blockage compared to isotype or to IL-10 treatment as measured via ELISpot 
(Supplemental Figure 2A).  Recovery of a population of IFN producing cells after anti-IL-
10 antibody treatment trended towards significance but was not significantly altered 
compared to isotype treated-PBMC (Figure 2.3A, C).  IL-10 production as measured by 
ELISA was significantly reduced after B7.H1 block as compared to IL-10 production from 
PBMC treated with isotype antibody (Figure 2.3D). The population of IL-10
+
 PBMC 
quantified via ELISpot increased after blockage of B7.H1 and stimulation with f-t. L.i., 
perhaps suggesting transformation of IL-10 expressing cells into IFN- coexpression, similar 
to previous findings [2] (Supplemental Figure 2B).  
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Figure 2.4.  PD-1/B7.H1 interaction necessary for suppression of proliferation but not 
IFN production during symptomatic VL– associated CD8+ T cell exhaustion.  Adherent 
PBMC treated with B7.H1 blocking antibody or IL-10 blocking antibody. PBMC stimulated 
as previous. (A) CD8+ cellular proliferation, n=13. (B) CD8+ PBMC IFNintracellular 
production, n=22. **p<0.01, via one way ANOVA with Tukey’s post-test. 
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 Blockage of the PD-1/B7.H1 interaction has been tested as a means for recovery of 
CD8+ T cell responses during chronic infections and has completed stage 1 clinical safety 
and efficacy trials for cancer immunotherapy [22, 23]. Mechanisms and effects of PD-
1/B7.H1 on CD4+ cells are poorly understood [8].  Blockage of B7.H1 was consistently 
effective in increasing the antigen-responsive population of CD4
+
 T cells from both 
asymptomatic and symptomatic VL animals, significantly increasing the percentage of cells 
able to proliferate and produce IFN- after B7.H1 treatment. PD-1 is therefore necessary for  
CD4
+
 T cell exhaustion during VL, and blocking the PD-1/B7.H1 interaction recovered a 
population of functional Th1 CD4
+
 T cells. 
 
Blockage of B7.H1/PD-1 recovers proliferation in exhausted CD8+ T cells but not 
IFNproduction. 
 Exhaustion of CD8+ T cells from peripheral blood in both asymptomatic and 
symptomatic animals was associated with a significant elevation of PD-1 surface expression 
(Figure 2.2). Blockage of the B7.H1/PD-1 interaction but not IL-10 significantly recovered  
both proliferation and IFN production within the CD4+ T cell population in response to 
stimulation with f-t L.i. (Figure 2.3). To evaluate the role of PD-1 and IL-10 in suppressing  
CD8+ T cell function, we blocked B7.H1 and IL-10 prior to stimulation with f-t L.i. and 
evaluated CD8+ T cells after 7 days in culture (Figure 2.4). 
 Consistent with B7.H1 blockage in the CD4+ T cell population, B7.H1/PD-1 
blockage on adherent PBMC significantly increased proliferative capacity in response to f-t 
L.i. in both asymptomatic and symptomatic animals (Figure 2.4A). As opposed to the CD4+ 
T cell population, blockage of IL-10 also significantly recovered CD8+ T cell function 
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Figure 2.5. L. infantum exhausted T cells do not undergo apoptosis or cell death in 
response to antigen stimulation. (A, B) Annexin V and PI (not shown) positivity was 
measured in asymptomatic or poly-symptomatic VL dogs after no stimulation and 
stimulation with 10 g/ml f-t L.i. for 7 days. PBMC were gated on CD4+ (A) or CD8+ (B) 
live lymphocytes based on isotype control. (C, D) Annexin V positivity was measured 
similarly to 3A, after blocking with isotype, IL-10, or B7.H1 blocking antibodies in CD4+ 
(C) and CD8+ (D). **p<0.01 via one way ANOVA with tukey post-test in GraphPad Prism 
5. Experiments included n=10 client-owned patients. 
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after f-t L.i. stimulation in asymptomatic animals (Figure 2.4A). However, within the CD8+ 
T cell population, blockage of PD-1 did not significantly recover IFN production in either 
asymptomatic or symptomatic dogs (Figure 2.4B). In symptomatic dogs, blockage of IL-10 
significantly recovered IFN production, although recovery was minimal compared to 
positive control (Figure 2.4B). This indicates in these asymptomatic and symptomatic dogs, 
the CD8+ T cell population recovery of IFN production is largely non-responsive to 
blockage of  PD-1/B7.H1. 
  
Antigen stimulation does not induce apoptosis in exhausted T cells 
 Previous research has demonstrated the step-wise manner in which CD4+ and CD8+ 
T cell populations progress through exhaustion [8, 9]. Shin et al. demonstrated the 
persistence of exhausted T cells in vivo, maintained through basal levels of proliferation and 
antigen stimulation independent of IL-7 and IL-15 [10]. To evaluate apoptosis of T cells 
during symptomatic VL, we evaluated PBMC at 7 days after f-t L.i. stimulation for Annexin 
V and propidium iodide positivity (Figure 2.5). Propidium iodide positivity indicative of cell 
death was low in all groups evaluated (data not shown).  Annexin V positivity was higher 
within the CD8+ T cell population than within the CD4+ T cell population from both 
symptomatic and asymptomatic animals across all experimental treatments (Figure 2.5A-D). 
However, Annexin V positivity was  higher in CD4+ and CD8+ T cells from asymptomatic 
animals than in T cells from symptomatic animals. After blockage of IL-10 or the PD-
1/B7.H1 interaction, CD4+ and CD8+ T cell apoptosis measured through Annexin V was 
still significantly lower within the symptomatic group than the asymptomatic group (Figure  
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Figure 2.6. B7.H1 block increased phagocyte superoxide production and decreased 
parasite load. (A) NBT assay performed on adherent PBMC from asymptomatic and 
symptomatic VL dogs after isotype, B7.H1, or IL-10 antibody treatment and stimulation with 
f-t L.i.. (B)  L. infantum-specific quantitative RT-PCR performed on PBMC DNA. Data 
presented as number of genomic copies of L. infantum/10
6
 PBMC from symptomatic dogs, 
after f-t L.i. stimulation (Li) compared to stimulation and addition of isotype, (left, Iso), anti-
IL-10 (middle, IL-10), or anti-B7.H1antibody (right, B7.H1). (A) n=13 and (B) n=7. 
*p<0.05, **p<0.01 , via one way ANOVA with Tukey’s post-test on averaged (A) or  log-
transformed (B) data. 
 
 
2.5C, D). There were no significant differences in Annexin V positivity between 
experimental treatments (Figure 2.5C, D). Blocking of B7.H1 in CD4+ T cells from 
symptomatic VL animals resulted in a slight trend toward increased Annexin V positivity, 
corresponding to the degree of recovered proliferation, with 3 animals that had increasing 
PBMC proliferation and also Annexin positivity, and 2 animals (also the lowest proliferators 
and producers of IFN from Figure 2.3B, C) without alteration in PBMC Annexin V 
positivity, proliferation, or IFN production. Within the CD8+ T cell population, there was 
no change in Annexin V positive cells in any experimental group (Figure 2.5D). This data 
suggests that in the presence of antigen, exhausted CD4+ T cells are unable to proliferate, but 
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are not induced to undergo apoptosis after continued antigen stimulation. This is consistent 
with previous reports in CD8+ exhaustion during LCMV infection of mice, where exhausted 
populations of CD8+ T cells were maintained in the continued presence of antigen [10]. 
However, within the CD8+ T cell population, recovery of proliferation did not correspond 
with an increase in Annexin positivity, indicating that this population does not respond to 
antigen by undergoing apoptosis after seven days in culture, even after recovery of 
proliferative potential. 
 
B7.H1 blockage improves the production of superoxide and parasite clearance in phagocytic 
monocytes.  
 Previous reports demonstrated the importance of ROI and RNI in reducing 
intracellular Leishmania burden [1, 14]. Phagocyte production of ROI and RNI required 
IFN production by T cells [15]. We demonstrated that blocking PD-1/B7.H1 signaling 
recovered a population of CD4+ T cells with IFN- production. We sought to determine how 
functional Th1 cell recovery altered phagocyte function, as phagocytes are both the target of 
L. infantum infection and necessary for L. infantum removal.  After PD-1/B7.H1 block, L.i. 
antigen-stimulated monocyte-derived phagocytes from asymptomatic and symptomatic dogs 
produced significantly more superoxide compared to all other treatments (Figure 6A, 
Supplemental Figure 2D). Nitric oxide production, as measured by Griess reaction performed 
on cell supernatants from identical PBMC cultures, had no significant differences between 
any experimental groups (Supplemental Figure 2C).  Dogs, like humans, have limited iNOS 
activity. There is continuing debate as to the importance of RNI in the killing of intracellular 
pathogens in species other than mice, including humans and dogs [15, 24]. 
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Blocking PD-1/B7.H1 increased superoxide production in adherent monocytes from 
symptomatic dogs chronically infected with L. infantum (Figure 2.6A).  Regaining an ability 
in these cells to produce parasite-lethal reactive oxygen species provides a link between 
restoration of CD4+ T helper function and improved monocyte-derived phagocyte function.  
We next wanted to identify whether this increase in ROI-producing phagocytes led to 
reduced intra-PBMC parasites ex vivo from VL asymptomatic and symptomatic dogs.  We 
quantified PBMC parasite load after PD-1/B7.H1 treatment via RT-PCR.  After B7.H1 block, 
parasite-stimulated PBMC from symptomatic animals had significantly fewer L. infantum 
parasites than f-t L.i.-stimulated PBMC or isotype-antibody treated PBMC using paired 
PBMC from the same dogs (Figure 2.6B).  The average reduction in L. infantum after B7.H1 
blockage was 0.58 log or 67.36%. While not significant, IL-10 block reduced parasite load in 
the four dogs with highest parasitemia (p=0.16) (Figure 2.6B, IL-10). Reduction of L. 
infantum in PBMC after blockage of B7.H1/PD-1 strongly suggests that PD1-PD1L signaling 
within the phagocyte has a significant suppressive role on the ability of phagocytes to induce 
an oxidative burst, permissive to L. infantum survival. 
 
DISCUSSION 
 Effective vaccination and immunotherapeutic strategies for VL have remained elusive 
[25]. Host and parasite factors regulating the balance of an asymptomatic state versus 
symptomatic clinical disease are incompletely understood for VL and are integral for 
addressing VL immunity [1]. Mice do not acquire symptomatic VL, therefore are largely 
inadequate for characterizing this host-pathogen interaction. In contrast, the canine model has 
similar pathogenesis to human VL and is valued as a target for public health interventions 
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including vaccination and therapy, in areas where dogs are the domestic reservoir of VL [4, 
26].  
 Using naturally-occurring canine VL, we identified decreased PBMC production of 
IFN, decreased CD4+ T cell proliferation to antigen stimulation, and increased IL-10 
production during clinical disease [4]; an exhausted phenotype. CD8+ T cell exhaustion has 
been identified in numerous infections, including disseminated cutaneous leishmaniasis [7-9, 
27]. CD8+ exhaustion is characterized by absence of antigen-specific responses including 
proliferation, CD8+ cytotoxicity, and IFN production [28]. Knowledge of CD4+ T cell 
exhaustion is less extensive [8]. Here we demonstrate for the first time concurrent CD4+ and 
CD8+ T cell exhaustion during naturally occurring symptomatic VL in a canine model, 
mediated by PD-1/B7.H1. These CD4+ T cells were phenotypically exhausted, with impaired 
proliferation and IFN production in response to L. infantum antigen. We demonstrate CD8+ 
T cell exhaustion, partially mediated by PD-1, which occurs prior to the onset of 
symptomatic disease, and prior to the onset of functional CD4+ T cell exhaustion.  It is 
logical, from an evolutionary standpoint that CD8+ T cells are more sensitive than CD4+ to 
tolerogenic stimuli, including prolonged antigen stimulation during chronic infection. This 
would protect infected cells from being the target of cytotoxic responses, and may 
significantly dampen pro-inflammatory stimuli with potential to induce host pathology [29]. 
Based on this clinical data, it is possible that concurrent CD4+ and CD8+ T cell exhaustion 
preceding the onset of clinical disease, contribute to the onset of symptomatic VL and non-
response to therapy. 
 CD4+ T cells from symptomatic animals also had a significant reduction in Annexin 
V positivity, with minimal apoptosis. CD8+ populations also had reduced Annexin V 
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positivity compared to control, although the CD8+ T cell population seemed to undergo a 
greater degree of apoptosis in culture than CD4+ T cells. Reductions in apoptosis could be 
due to the clonal deletion of antigen specific T cells or to the non-response of these cells. 
Within both CD4+ and CD8+ T cell populations, blockage of B7.H1 significantly increased 
proliferative capacity and in the CD4+ population IFN. This makes clonal deletion unlikely, 
as an antigen-specific population could be recovered. A more likely explanation is the 
antigen-addiction theory put forth by Wherry, supported by previously conducted research 
[8, 10]. This would suggest that the CD8+ and CD4+ T cell populations contain antigen-
experienced cells that do not respond to antigen by undergoing proliferation, but also do not 
undergo apoptosis after antigen stimulation. Possible mechanisms for this would include 
antigen-driven survival, perhaps through cytokines such as IL-2 and T cell receptor 
engagement, or less likely through replicative senescence, which occurs due to epigenetic 
modification and telomere shortening during aging and prolonged cellular replication [30-
32]. 
 We also identified increased APC superoxide production and reduced intracellular 
parasites ex vivo after PD-1/B7.H1 block, indicating a role for this signaling pathway in 
altering phagocyte function as VL progresses. The importance of production of ROI and RNI 
are well documented components of effective immunity against Leishmania species and 
other intracellular pathogens [1]. Due to the dramatic alterations in both phagocyte, CD4+ T 
cell, and CD8+ T cell effector function after ex vivo PD-1/B7.H1 block, this therapy may be 
a means of inducing increased pro-inflammatory phagocyte function, and therefore a strong 
target for VL immunotherapy. 
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 A recent report demonstrates the importance of CD4+ T cell exhaustion in the 
development of CD8+ T cell exhaustion [33]. In the presence of chronic infection it is likely 
that these two processes are extensively intertwined. Previous studies aimed at VL 
immunotherapy have targeted IFN, blocking IL-10, or using TLR agonists [21, 34]. Limited 
success of these immunotherapeutic approaches suggests that there are other, perhaps more 
significant, mechanisms of immune dysregulation during VL. This study demonstrates 
concurrent CD4+ and CD8+ T cell exhaustion, often present prior to the onset of 
symptomatic VL, mediated in part by significantly elevated surface expression of 
coinhibitory molecule PD-1. T cell exhaustion may be a major contributor to the onset of 
symptomatic VL, and demonstrates potential as a target for immunotherapy. 
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ABSTRACT 
 Chronic kidney disease is a major health burden globally, and a major contributor to 
both human and companion animal morbidity and mortality. Renal complications are 
common as a sequelae to canine (>96% of cases) and human visceral leishmaniasis (VL) (25-
30% of cases). Despite the high incidence of infection-mediated glomerulonephritis, little is 
known about the pathogenesis and mechanisms of VL-associated renal disease. Due to 
similarities in the immune response, immunopathology, clinical signs, and pathophysiology, 
L. infantum-infected dogs serve as a naturally-occurring model of VL and VL-associated 
glomerulonephritis.  The study objectives were to identify glomerular alterations associated 
with glomerular injury and evaluate  glomerular cellular responses during canine VL-
associated glomerulonephritis.  We evaluated a cohort of dogs infected with L. infantum from 
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the United States (n=15), L. infantum-infected dogs from an endemic area of Northeastern 
Brazil (n=10), and Leishmania-negative controls (n=5). Analysis of glomeruli demonstrated 
the presence of Leishmania antigen, IgG, and complement protein C3b. Evaluation of 
glomerular Nod-Like Receptor Protein 3 (NLRP3) and Microtubule-Associated Protein 1 
Light Chain 3 (LC3) suggest alterations in inflammasome and autophagosome activity 
associated with lesion severity and clinical disease status. Membranoproliferative 
glomerulonephritis type I (24/25, 96%), with interstitial lymphoplasmacytic nephritis (23/25, 
92%), and glomerular and interstitial fibrosis (12/25, 48%) were the predominant lesions.  
Ultrastructural evaluation of glomeruli from animals with clinical VL   identified mesangial 
cell proliferation, mesangial cell interposition, and sub-endothelial and mesangial segmental 
electron-dense protein deposits.  VL glomerulonephritis was mediated by antibody complex 
and complement deposition within the glomerulus, leading to NLRP3 inflammasome 
positivity, concomitant with LC3 autophagosome  increased presence in dogs with clinical 
VL and renal failure. These findings elucidate potential novel mechanisms of glomerular 
responses to pathologic insult. 
 
INTRODUCTION 
 Kidney disease is a major contributor to morbidity and mortality in canine and human 
populations. In the United States, there are an estimated 4.4 million non-institutionalized 
adults with renal disease, and renal disease ranks ninth as a cause of death in the United 
States [1, 2].  Health care costs associated with end-stage renal disease (ESRD) resulting in 
the necessity for long-term dialysis were approximately $33 billion USD in 2010 [3, 4]. 
Immune-mediated glomerular disease accounts for a large percentage of ESRD cases, with a 
wide spectrum of causes, lesions and sequelae [1]. The traditional WHO classification 
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scheme for immune-mediated glomerulopathy is based upon histopathologic and 
ultrastructural characteristics, categorizing cases as membranous or membranoproliferative 
[5].  Membranoproliferative glomerulonephritis is traditionally further classified as Type I, 
II, or III based on the location and character of protein deposits [5].  These characterizations 
are however, based on morphology rather than specific cause, and can often be found a 
spectrum of changes within a single biopsy, or can differ by the clinical stage by a single 
causative agent.  
 Recent efforts to reclassify membranoproliferative glomerulonephritis (MPGN) by 
pathogenesis are thought to be more predictive of clinical outcome and may help target 
therapy.  The new classification scheme uses immunofluorescence or immunohistochemistry 
to define lesions as immune-complex MPGN (with IgG, IgM, and/or complement), as 
immunoglobulin negative C3 glomerulopathy, or dense deposit disease [5, 6]. The podocyte, 
a versatile, long-lived cell type constructing the glomerular filtration slit, and the mesangial 
cell, which is a major resident phagocyte within the glomerular mesangium, play definitive 
roles in MPGN.  As previously mentioned, the reaction of mesangial cells and ultrastructural 
changes and eventual apoptosis of glomerular podocytes are the basis for traditional 
classification of MPGN.  Even with a greater understanding of the root causes of MPGN and 
their association with therapeutic efficacy and prognosis, relatively little is known of how the 
glomerular apparatus (podocytes, mesangial cells, endothelial cells) responds to injurious 
inflammatory stimuli. Multiple reports have demonstrated the importance of autophagy in the 
maintenance of the GBM as a normal function of podocytes [7-10]. Podocyte specific 
knockout of LC3, a major autophagy protein, results in a phenotype of glomerulosclerosis 
due to the accumulation of poly-ubiquitinated proteins by 24 months [7]. In addition 
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elevations in LC3 have been previously identified in response to the increased glucose levels 
of a rat model of diabetic nephropathy, and in patients with Fabry disease [11, 12]. 
Furthermore, recent studies indicate the intracellular degradation of collagen stimulated by 
TFG- in kidneys is dependent upon autophagy-associated protein Beclin-1 [13]. Regulation 
of renal fibrosis and the clearance of immune complexes during inflammatory MPGN is 
potentially regulated through autophagy-associated pathways. 
 Renal disease due to glomerulonephritis and interstitial nephritis is a common clinical 
sign of visceral leishmaniasis due to Leishmania infantum, occurring in greater than 96% of 
symptomatic dogs and approximately 25-30% of human cases [14-20]. Alterations in renal 
function during active VL are generally reversible with anti-Leishmania therapy [19-21]. 
However, VL-associated kidney disease is progressive and without therapy can result in 
ESRD (approximately 1.5% of human cases, >25% canine cases) [19, 21, 22]. Previous 
reports regarding the pathophysiology of VL-associated renal disease are conflicting, with 
separate studies showing either the presence or absence of Immunoglobulin G (IgG) and 
complement protein C3 [23, 24]. In addition, previous characterizations of the subtype of 
MPGN have varied greatly [15, 16, 25].  Accurate assessment of VL-associated glomerular 
lesions early in their progression is essential to determining an efficacious treatment regimen 
and is also of prognostic value [26]. 
 Inflammasomes are protein complexes that respond to a variety of cellular stressors as 
well as direct receptor-ligand interactions [27]. The Nod-like receptor protein 3 (NLRP3) is a 
well characterized inflammasome protein that responds to intracellular pathogen associated 
molecular patterns (PAMPs) and stress-related molecules [27].  NLRP3 responds to 
numerous PAMPS including lipopolysaccharide (LPS), muramyl-dipeptide (MDP), single 
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and double stranded bacterial RNA, and TLR 7/8 ligand R848 [28-32]. NLRP3 can also be 
activated through elevations in endogenous molecules, including ATP, urate crystals, other 
particulate matter, zymogen, and other bacterial pore-forming toxins [29, 33-35]. In the 
kidney, IL-1 and IL-18 are key pro-inflammatory mediators of renal disease [36]. In 
addition, a single study demonstrate the activation of NLRP3 mediated glomerular injury 
stimulated by NAPDH oxidase activation [37]. Immune complex deposition within the 
subendothelial space and within the glomerular mesangium may drive pro-inflammatory 
podocyte and filtration apparatus injury through the activation of NLRP3. 
 This study characterized the lesions and type of glomerulonephritis associated with 
chronic infection with Leishmania infantum. These renal alterations, present both in 
symptomatic disease and prior to the onset of symptomatic disease, were primarily of a 
membranoproliferative type I, with subendothelial and mesangial electron dense deposits and 
endocapillary and mesangial proliferation. With symptomatic disease, lesions were 
associated with a higher rate of renal fibrosis and segmental glomerulosclerosis.  Protein 
deposits during VL-associated GMN were composed of Leishmania infantum antigen, IgG, 
and complement protein C3. Furthermore, this study is the first, to our knowledge, to 
evaluate the association of LC3+ autophagy and NLRP3+ inflammasome activation with 
clinical stage of disease during MPGN. This data suggests a potential role for both NLRP3 
and LC3+ autophagy during the pathogenesis of immune complex mediated renal disease and 
VL-associated MPGN. 
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MATERIALS AND METHODS 
Animals - Study animals were enrolled for this study based on IFAT serology as previously 
described [38] and euthanized with owner’s consent. Necropsies were performed by 
pathologists at  Iowa State University College of Veterinary Medicine and at UFRN in Natal, 
Brazil. Full or partial necropsies were performed on each animal with gross evaluation and 
tissues harvested for histopathologic  examination from each animal. 
 
Histopathology - Tissues were fixed in 10% neutral buffered formalin, paraffin-embedded 
and processed for routine histopathologic evaluation. Sections were stained with hematoxylin 
and eosin (HE), Masson's trichrome, and periodic acid Schiff - methenamine silver (PASM). 
The sections were analyzed by light microscopy (BX41, Olympus), and the renal changes 
were classified according to the criteria of the World Health Organization for classification 
of the morphologic pattern of glomerulonephritis. Lesions were scored from Grade 1-4 based 
on expansion of the mesangium, mesangial fibrosis, prominence of capillary loops, peri-
glomerular inflammation, and the percentage of sclerotic glomeruli. 
 
Electron microscopy - Renal tissue was fixed in 2.0% glutaraldehyde in 0.1 M phosphate 
buffer, pH 7.4. Ultrathin sections were stained for analysis by transmission electron 
microscopy. 1 mm tissues were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate 
buffer. After fixation, samples were rinsed in cacodylate buffer, post-fixed in 2% osmium 
tetroxide, dehydrated in alcohols, cleared in propylene oxide and embedded in Eponate 12 
epoxy resin. Ultrathin sections were cut, stained with uranyl acetate and lead citrate and 
examined with a Tecnai 12 G
2
 electron microscope. 
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Immunohistochemistry – 3 micron sections were stained with the following antibodies at the 
indicated concentrations: poly-clonal canine anti-L. infantum (hyperimmune serum, 1:500 
dilution), poly-clonal anti-canine IgG (2mg/ml, 1:6000 dilution) (Immunovision, Springdale, 
AZ, USA), poly-clonal anti-canine IgM (2mg/ml, 1:2000) (Immunovision, Springdale, AZ, 
USA), poly-clonal anti-canine C3b (1 mg/ml, 1:200 dilution) (Bethyl Labs, Montgomery, 
Texas) (2mg/ml). For IgG and IgM labeling, slides were pre-heated to 57
o
C for 30 minute 
prior to deparaffinzation. Endogenous peroxidases were inhibited by addition of 3% H2O2 
twice for 10 minutes, followed by 3 rinses in ultrapure water. Antigen retrieval was 
performed at 96
o
C in pH 10 Tris buffer for 5 minutes, followed by transfer into -20
o
C for 20 
minutes. Samples were blocked with10% normal goat serum in PBS for 20 minutes prior to 
primary antibody addition.  Samples were washed and stained with multilink (Biogenex, 
Fremont, CA, USA) and developed with Streptavidin HRP and Nova Red (Vectorlabs, 
Burlingame, CA, USA) prior to counterstaining with hematoxylin. C3b staining was similar, 
but with antigen retrieval in Tris HCL pH 1 at 96
o
C for 20 minutes.  Labeling for Leishmania 
antigen was performed as previously published [39]. Procedure was similar, but with primary 
antibody staining overnight at 4
o
C.  Appropriate controls were included in each experiment. 
 
Immunofluorescence -  Formalin fixed paraffin-embedded sections and cryosections were 
labeled with poly-clonal canine cross-reactive anti-human LC3 (0.2 mg/ml, 1:50 dilution) 
(AbCam, Cambridge, MA), and poly-clonal canine cross-reactive anti-human NALP3 (0.5 
mg/ml, 1:100 dilution) (AbCam, Cambridge, MA). Sections were washed and cryosections 
were fixed with Acetone for 5 minute then air dried for 30 minutes. Sections were then  
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Figure 3.1. Kidney sections from L. infantum-infected dogs evaluated for lesions 
associated with GMN.  (A) Glomeruli were diffusely expanded by mesangial and 
endocapillary proliferation with hypersegmentation of the glomerular tuft and segmental 
thickening of Bowman’s capsule. Hematoxylin and Eosin (HE, 400x). (B) Segmentally, renal 
glomeruli become sclerotic, with prominent lymphoplasmacytic and histiocytic interstitial 
nephritis, and fibrosis of Bowman’s capsule and the glomerular tuft. HE (400x). (C) 
Interstitial nephritis with prominent multifocal peri-glomerular and perivascular 
accumulations of plasma cells, lymphocytes, and macrophages. HE (100x). (D) 1000x 
magnification of C. Multifocal peri-glomerular aggregates of plasma cells, lymphocytes, and 
macrophages, occasionally containing intracellular protozoal Leishmania (arrow). HE. (E) 
Glomeruli have a robust expansion of the mesangium with mesangial cell proliferation and 
interposition. Glomerular basement membranes commonly have splitting with double 
contours. PASM (400x). (F) 1000x magnification of mesangial cell interposition and 
expansion of the mesangium (asterisk), and double contours of the glomerular basement 
membrane (between arrows). PASM. 
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permeabilized with 0.3% Triton X 100 (Sigma) in 1x PBS for 10 minutes. Sections were then 
washed and treated with blocking immunofluorescence buffer (2% FCS, 1% BSA, 0.1% 
Tween 20 in 1x PBS) for 30 minutes prior to labeling with primary antibodies overnight at 
4
o
C. Secondary antibodies for LC3 (Texas Red conjugated anti-rabbit IgG) and NLRP3 
 (Alexafluor 400 conjugated anti-goat IgG) were used at a concentration of 2 g/ml for 60 
minutes at room temperature.  Coverslips were added using Prolong Gold Anti-fading 
Reagent (Life Technologies, Grand Island, NY USA) and analyzed via confocal microscopy. 
Secondary antibody and unstained controls were included for each experiment. 
 
Image analysis – Glomeruli were imaged individually and analyzed with Image J using 
threshold analysis to calculate the percentage of glomerular area with positive staining, the 
number of positive cells as a percentage of total glomerular cells counted as DAPI-positive 
nuclei in fluorescent images, and density of positive staining. 
 
Statistical analysis -  Statistical analysis was conducted with one way ANOVA or pair-wise 
student’s t-tests as appropriate conducted with Graph Pad Prism 5 with Tukey’s post-test,  
statistical significance at =0.05. 
 
RESULTS 
 VL-associated glomerulopathy lesions are present in asymptomatic animals, with GBM 
expansion and fibrosis associated with symptomatic disease. 
 To assess the onset of glomerular lesions and their association with symptomatic VL, 
we evaluated renal samples from 13 asymptomatic and 12 symptomatic dogs from the United 
States and Brazil diagnosed as infected with Leishmania infantum, and kidneys from five 
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non-renal disease control dogs presented to Iowa State University Department of Veterinary 
Pathology. Animals were staged prior to necropsy based on clinical presentation, including 
lymphadenopathy, palpable liver or spleen, and skin lesions typical of VL. The 15 dogs from 
the United States were also evaluated via full physical exam and fecal exam for co- 
***p<0.001 
 
morbidities. The 10 dogs from Brazil were more likely to be symptomatic at the time of 
presentation (7/10), and may have had additional co-morbidities, including malnutrition, 
helminth infection, or rickettsial disease that were not present in the U.S. cohort.  
 Glomerular lesions were present at a high rate in both asymptomatic and symptomatic 
dogs. Ninety-six percent (24/25) of all dogs had hypercellularity within the glomerulus, 
based on routine histopathologic examination (Table 3.1, Figure 3.1A). Glomeruli were large 
and hypercellular, typical of mesangial cell and capillary endothelial proliferation (Figure 
3.1A). Glomerular hypersegmentation, with a distinct lobular appearance of glomerular tufts,  
Table 3.1. Microscopic lesion summary of VL-associated glomerulopathy in dogs 
 
Asymptomatic Symptomatic Total 
Mesangial proliferation 92.31%, (12/13) 100.00%, (12/12) 96.00%, (24/25) 
Interstitial nephritis 92.31%, (12/13) 91.67%, (11/12) 92.00%, (23/25) 
Glomerular 
hypersegmentation 
92.31%, (12/13) 100.00%, (12/12) 96.00%, (24/25) 
Glomerular and interstitial 
fibrosis 
7.69%, (1/13) 91.67%, (11/12)*** 46.00%, (12/25) 
Double contour GBM 15.38%, (2/13) 91.67%, (11/12)*** 52.00%, (13/25) 
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Figure 3.2. Ultrastructural lesions of VL-associated glomerulonephritis are 
characteristic of Type I Membranoproliferative Glomerulonephritis. Renal cortical 
sections were harvested from dogs with symptomatic VL. Renal tissue was fixed in 
glutaraldehyde and analyzed via Transmission electron microscopy (A) Renal glomerular 
section with mesangial cell hypercellularity and mesangial cell capillary interposition 
(asterisk). Mesangial and subendothelial deposits were prominent (arrows). Transmission 
electron microscopy (4,320x). (B) 27,600x magnification of mesangial cell interposition. 
Podocyte foot processes were separated from the glomerular basement membrane by 
mesangial cell processes with the presence of electron dense material within both the GBM 
and mesangial cell. TEM (27,600x). (C) Prominent subendothelial deposits within the 
glomerular capillary, with segmental thickening of the GBM (between arrows). TEM 
(16,400x) (D) 27,600x magnification of segmental subendothelial thickening.  Note the 
relative sparing of podocyte foot processes with only occasional blunting and fusion (arrow). 
TEM (27,600x) (E) Endocapillary hypercellularity with a plump and reactive endothelial cell 
with separation from the GBM by subendothelial deposits (arrow). TEM (7,160x). (F) 
27,600x magnification of subendothelial deposits with interposed cellular processes 
separating the endothelial cell from the GBM. TEM (27,600x).   
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was also present at a high rate in both asymptomatic and symptomatic animals (96%, 24/25 
total cases) (Table 3.1, Figure 3.1A). Interstitial nephritis, characterized by infiltration of 
macrophages, lymphocytes and plasma cells into peri-glomerular and peri-vascular areas was 
present equally in both asymptomatic and symptomatic dogs, at 92% of both experimental 
groups (Table 3.1, Figure 3.1C, D). Factors predictive of symptomatic disease were 
irreversible lesions typically associated with chronicity. Expansion of mesangial matrix with 
mesangial cell interposition (Figure 3.1, E, F asterisk)  and segmental splitting of the 
glomerular basement membrane (Figure 3.1F, arrows) analyzed via periodic acid Schiff’s – 
methanamine silver (PASM) stain was significantly increased within the symptomatic group 
(91.67%, 11/12) compared to the asymptomatic group (15.38%, 2/13) (OR=60.5, CI= 4.76, 
769)(Table 3.1). The rate of glomerular and interstitial fibrosis measured via routine 
histopathology, was also significantly increased within the symptomatic group (91.67%, 
11/12)(OR=132, CI=7.33, 2377) compared to the symptomatic group (7.69%, 1/13) (Table 
3.1, Figure 3.1B). These findings suggest that while membranoproliferative lesions were 
present both during asymptomatic and symptomatic VL. Lesions of chronicity, particularly 
fibrosis and expansion of mesangial matrix, were significantly associated with the presence 
of symptomatic VL. 
 
Lesions of VL-associated glomerulonephritis are membranoproliferative type I. 
 Determination of membranoproliferative glomerulonephritis type is primarily based 
on ultrastructural evaluation of glomeruli [6]. The traditional WHO classification scheme for 
immune-mediated glomerulopathy utilized histopathologic and ultrastructural characteristics 
to classify lesions. as membranous (spiked dense protein accumulations within the GBM), 
and membranoproliferative (protein deposits within the GBM and mesangium driving 
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proliferation of mesangial cells, endocapillary proliferation, capillary remodeling, and 
mesangial cell interposition with duplication of glomerular basement membranes) [5].  
Membranoproliferative glomerulonephritis is traditionally further classified as 1) MPGN 
Type I, with subendothelial and mesangial protein deposition, 2) MPGN Type II, with 
electron-dense intra-membranous and mesangial deposits, also known as dense deposit 
disease, or 3) MPGN Type III, with subendothelial, subepithelial, and/or complex deposits 
with fraying of the lamina densa [5].  These characterizations are however, based on 
morphology rather than specific cause, and can often be found a spectrum of changes within 
a single biopsy, or can differ by the clinical stage by a single causative agent. Previous 
reports of VL-associated glomerulonephritis identify lesions ranging from 
membranoproliferative in nature to end-stage renal disease with glomerulosclerosis [15, 16, 
23-25, 40].  The ultrastructural changes evident in this study were subendothelial, 
intramembranous, and/or mesangial, with blunting and fusion of podocyte foot processes. In 
this study, we also found pronounced mesangial cell proliferation and interposition (Figure 
3.2A, B asterisk), with primarily subendothelial and mesangial electron dense deposits 
(Figure 3.2A, C, D arrows).  Remarkably, given the expansion of the glomerular basement 
membrane, podocyte foot processes were largely unaffected in asymptomatic cases, with 
only occasional fusion, and rare blunting and separation (Figure 3.2D, F). Endocapillary 
proliferation and endothelial separation from the glomerular basement membrane was 
pronounced in all cases (Figure 3.2E, F).  The changes of subendothelial and mesangial 
electron dense deposits with mesangial cell interposition and endocapillary proliferation are 
consistent with membranoproliferative glomerulonephritis type I. The accurate 
characterization of glomerular lesions is becoming increasingly important, with the  
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Figure 3.3. VL-associated MPGN is the result of deposition of Leishmania infantum 
antigen, IgG, and C3. Formalin-fixed paraffin embedded renal cortical sections from dogs 
naturally infected with Leishmania infantum or negative controls were evaluated for 
endocapillary and mesangial deposits of L. infantum antigen (A), complement protein C3 
(B), Immunoglobulin G (C), and for glomerular fibrosis (D). (A) Leishmania infantum 
antigen immunohistochemistry with hematoxylin counterstain. (B) C3 
immunohistochemistry with hematoxylin counterstain. (C) Immunoglobulin G 
immunohistochemistry with hematoxylin counterstain. (D) Masson’s trichrome staining for 
collagen. (E) The percentage of glomerular area staining positive for L. infantum antigen in 
normal controls, asymptomatic VL, and symptomatic VL, gated via threshold analysis in 
Image J. (F) The percentage of glomerular area staining positive for C3 in normal controls, 
asymptomatic VL, and symptomatic VL, gated via threshold analysis in Image J. (G) The 
percentage of glomerular area staining positive for IgG in normal controls, asymptomatic 
VL, and symptomatic VL, gated via threshold analysis in Image J. (H) All Images (A-D) are 
were obtained at 400x magnification. The percentage of glomerular area staining positive for 
Trichrome (Collagen) in normal controls, asymptomatic VL, and symptomatic VL, gated via 
color threshold analysis in Image J. Data is presented as population graphs with SEM. 
Statistical analysis was performed using GraphPad Prism 5.  Analysis was conducted via 
One-way ANOVA with Tukey’s post-test, *p<0.05, **p<0.01.  
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increasing number of randomized clinical trials evaluating targeted biotherapeutics, to 
address cases on an individualized basis [5]. Accurate typing is also prognostically valuable, 
with a documented 5 fold reduction in ESRD based on the extent of GBM and mesangial 
deposits and the severity of the glomerular lesions [26]. 
 
Glomerular basement membrane deposits are associated with complexes primarily composed 
of Leishmania antigen, IgG, complement protein C3b, and increased collagen.  
 New efforts to correlate the classification system for MPGN with clinical severity and 
therapeutic outcome, have led to reclassification of glomerular lesions based not only on the 
location of the deposits, but on the components of the electron dense deposits [5].  Previous 
reports of canine VL are conflicting; one demonstrated presence of Leishmania antigen, but 
absence of complement, IgG, or IgM, and another demonstrated presence of IgG, IgM, and 
C3 [23, 24].  In this study we evaluated the presence of IgG, IgM, C3, and Leishmania 
antigen in FFPE sections from asymptomatic and symptomatic animals.  Glomeruli were 
imaged, and the area of the glomerular tuft quantified via mask creation in Image J. A 
threshold of positivity was created using color threshold analysis, and IHC positivity was 
quantified as area IHC positive staining as a percentage of total glomerular area.  In both 
asymptomatic and symptomatic animals the level of labeling of Leishmania antigen was 
significantly elevated compared to the five control animals (Figure 3.3A, E).  Labeling for 
IgG via immunohistochemistry was also significantly elevated as a percentage of glomerular 
area in both the asymptomatic and symptomatic groups compared to normal dogs (Figure 
3.3C, G). There was no difference in IgM staining within the glomerulus between 
asymptomatic, symptomatic, or control dogs (data not shown). Immunohistochemical  
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Figure 3.4. VL-associated MPGN is associated with elevated vacuolar-associated LC-3 
autophagy protein and the NLRP3 inflammasome. Frozen and/or formalin-fixed parafin-
embedded renal cortical sections were labeled with immunofluorescent antibodies and 
imaged and counted via confocal and immunofluorescence microscopy to evaluated the 
presence of LC3 positive autophagy-associated vacuoles and increased presence of NLRP3 
positive inflammasomes. (A) Immunofluorescence of renal glomeruli from a secondary 
antibody control sample (top row), L. infantum negative dogs (second row), and dogs with 
symptomatic VL (bottom row). Cells were stained with DAPI, (left column), labeled for 
NLRP3 (anti-human polyclonal, Alexafluor 488, middle left), LC3 (anti-human polyclonal, 
Texas Red, middle right). (B, C) Population graphs of the percentage of LC3 positive cells as 
a percentage of total glomerular nucleated cells from L. infantum negative (B, C), 
asymptomatic (B), and symptomatic dogs (B, C) from formalin fixed paraffin-embedded (B) 
and frozen cryosections (C). (D, E) Population graphs of the percentage of NLRP3 positive 
cells as a percentage of total glomerular cells from L. infantum negative (D, E), 
asymptomatic (D), and symptomatic dogs (D, E) from formalin fixed paraffin-embedded 
sections (D) and frozen cryosections (E). Data was analyzed via one-way ANOVA with 
Tukey’s post-test for significance. *p<0.05, ***p<0.01. 
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labeling of complement protein C3b was increased as a percentage of glomerular area in both 
asymptomatic and symptomatic dogs compared to control. Asymptomatic animals trended  
higher in C3b labeling than symptomatic animals but this was not statistically significant 
(p=0.17). This is consistent with presence of serum hypergammaglobulinemia in dogs with 
symptomatic leishmaniasis.  Immunoglobulin G and L. infantum antigen deposits were 
present in asymptomatic dogs as well, suggesting deposition was associated with a mesangial 
and endocapillary proliferative response, and sub-endothelial deposits, but is present prior to 
the onset of symptomatic VL. 
 We also evaluated the degree of mesangial collagen and glomerular fibrosis via 
Masson’s Trichrome. We utilized similar image analysis gating the color threshold on the 
blue staining typical of collagen.  Trichrome-positive, collagen staining was increased in both 
the asymptomatic and symptomatic animals and symptomatic dogs had significantly greater 
staining of collagen than asymptomatic dogs (Figure 3.3D, H).  This data indicates the degree 
of glomerular fibrosis is closely associated with the clinical status of L. infantum - infected 
dogs. 
 
Increased NLRP3 is associated with clinical disease and glomerular inflammation. 
 Glomerular immune complex deposition and subsequent impairment of the 
glomerular filtration apparatus has been previously associated with numerous pro-
inflammatory cytokines, including IL-1 with fibrosis stimulated by TGF. Previous 
reports of VL-associated glomerulonephritis demonstrated increased expression of the 
adhesion molecules such as ICAM and P-Selectin [23]. Numerous stimuli can result in 
NLRP3 inflammasome activation in renal tubular epithelium, including uric acid crystals, 
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amyloid, cholesterol crystals, and high glucose [33, 35, 42]. This activates caspase 1-
mediated IL-1production. To evaluate the possibility that the inflammasome protein 
NLRP3 was associated with the progression of VL-associated MPGN, we labeled formalin-
fixed paraffin embedded sections (Figure 3.4D) and cryosections (Figure 3.4A, E) with 
immunofluorescence for NLRP3 (Figure 3.4, column 3, D, E). NLRP3 positivity was 
significantly elevated in symptomatic dogs compared to normal dogs (Figure 3.4A, column 
3, D, E).. NLRP3 was typically present within the cellular cytoplasm, as fine punctate 
cytoplasmic staining either near the cell periphery or diffusely throughout the cell cytoplasm, 
and occasionally within vacuolar structures. This data suggests an association between 
NLRP3 inflammasome induction and the severity of renal disease due to Leishmania 
infantum. This could be causative or the result of prolonged pro-inflammatory and antigen 
stimulation within the glomerulus. 
 
Autophagy protein LC3 is associated with symptomatic infection with L. infantum. 
 Macroautophagy is an integral component of organelle and protein recycling within 
cells, with the most abundant macroautophagy in long-lived cells of the body including 
neurons, cardiomyocytes, and glomerular podocytes, and within metabolically active cells 
such as skeletal muscle and renal tubular epithelium. The importance of macroautophagy in 
podocyte maintenance of the glomerular filtration apparatus has been previously 
demonstrated in podocin-conditional LC3 knockout mice [7].  These mice develop protein-
losing nephropathy and eventual glomerulosclerosis due to the accumulation of poly-
ubiquitinated protein with death by 24 weeks of age [7]. In macrophages, the autophagy 
machinery can also be engaged in response to pathogen-associated molecules, including 
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immune complexes [43]. To evaluate if increased LC3 was associated with the precipitation 
of clinical renal disease and the onset of identifiable MPGN due to VL, we labeled formalin-
fixed paraffin-embedded (Figure 3.4 B, C) or frozen cryosections (Figure 3.4A, C) from the 
renal cortex for LC3, then quantified LC3+ cells as a percentage of total glomerular cells 
from L. infantum negative, asymptomatic, and symptomatic dogs. The percentage of 
glomerular cells with LC3+ compartments was significantly elevated in symptomatic dogs 
compared to control animals (Figure 3.4A, B, C). Interestingly, labeling for LC3 and NLRP3 
was segmental within glomeruli, consistent with the segmental deposits demonstrated by 
TEM. As a percentage of total glomerular cells LC3 and NLRP3 were consistently elevated 
in glomeruli of all stages of lesion severity, including those with a robust proliferative 
mesangium and those with a higher degree of collagen and fibrosis (data not shown). This 
data demonstrates a strong association between the relative presence of LC3+ compartments 
within the glomerulus, the severity of MPGN due to VL, and symptomatic VL.  This increase 
could be the result of increased cellular stress and the subsequent recycling of cellular 
organelles or a direct result of immune complex, complement, and antigen deposition within 
the glomerular mesangium and subendothelial region of the glomerular basement membrane. 
 
DISCUSSION 
 Chronic kidney disease is a major global health problem, for which approximately 
5% of all health care expenditures are utilized [2-4].  This largely is the result of therapy for 
end stage renal disease (ESRD) including long-term dialysis and renal transplantation.  Renal 
disease was also the ninth leading cause of death in the United States in 2010, with 
approximately 50,406 fatalities [44]. The incidence of kidney disease and associated 
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mortality has increased steadily since 1980 in the United States, and is higher in developing 
regions with high rates of hepatitis C-associated glomerulonephritis and relatively lower 
access to dialysis and renal transplantation [1]. Even so, the physiology of the glomerulus 
including specific responses of glomerular podocytes and mesangial cells, are incompletely 
understood.  These cells, in conjunction with vascular endothelial cells, form and maintain 
the glomerular filtration apparatus responsible for filtration of 20% of the body’s volume of 
blood with each heartbeat. An understanding of the molecular pathophysiology of 
glomerulonephritis will lead to novel therapeutics and diagnostics for intervention and early 
recognition of renal disease, reducing the need for costly treatment of ESRD and the overall 
need for renal transplantation. 
 Renal disease is a common clinical complication of human and canine VL.  Nearly 
100% of clinically effected dogs have renal lesions and approximately 30% of overall human 
cases with a rate of acute kidney injury in children of approximately 25-45.9% [14-20]. 
These lesions are largely responsive to therapy with antimonials or amphotericin B [20, 21, 
45]. However, approximately 1.5% of patients present with renal failure [19]. Renal lesions 
in both humans and dogs due to visceral leishmaniasis have been previously characterized as 
progressive glomerulonephritis including mesangial proliferative, membranoproliferative, 
focal segmental glomerulosclerosis, and minimal change glomerulonephritis, and a smaller 
percentage with crescentic glomerulonephritis [16, 23, 24, 40]. These morphologic 
classifications may be largely indicative of the chronicity of glomerular injury, but have little 
correlation with the mechanism of pathologic insult or the glomerular response to said insult. 
In our study, every classification of glomerulonephritis could be found in individual 
glomeruli from the same renal cortical section in some cases. Recent efforts to expand the 
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WHO classification model to include a molecular characterization of the glomerular deposits 
in addition to routine histologic evaluation and electron microscopy have added additional 
information regarding the pathogenesis of specific forms of glomerulonephritis [5]. This 
provides guidance for targeted therapeutics and may elucidate molecular targets for therapy 
to reduce long-term renal insufficiency and ESRD. 
 In this study, we characterized the primary morphologic changes associated with VL-
associated glomerulonephritis and the molecular components of the glomerular deposits 
characteristic of VL glomerulonephritis.  We have classified VL-associated 
glomerulonephritis as membranoproliferative type I glomerulonephritis, associated with 
segmental subendothelial and mesangial deposits of L. infantum antigen, IgG, and 
complement protein C3. Furthermore, our study utilized VL-associated glomerulonephritis as 
a model to evaluate the association of macroautophagy marker LC3 and NLRP3 with 
symptomatic disease and the severity of glomerular lesions. This study indicated LC3+ 
compartments and NLRP3 protein indicative of the NLRP3 inflammasome are significantly 
increased during asymptomatic and symptomatic VL compared to controls. Macroautophagy 
in response to immune complex deposition within the glomerulus may be a major mechanism 
for removal of accumulated proteins, complement, and immune complexes from the 
glomerular filtration slit. NLRP3 activation in response to immune complex deposition is a 
possible source for increased IL-1 and IL-18 within the kidney, which serves as an 
important chemotactic and pro-inflammatory stimulus. 
 Multiple studies have evaluated the morphology and ultrastructural characteristics of 
renal lesions due to VL in dogs and humans [16, 20, 23, 24, 46]. Previous characterizations 
described a wide array of morphologic changes, primarily of a membranoproliferative and 
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mesangial proliferative type [16, 20, 23, 24, 46]. Dogs with symptomatic VL typically have a 
hypergammaglobulinemia and a high degree of circulating parasite antigen [38].  It is logical 
that immune complexes comprise glomerular deposits responsible for VL-associated MPGN. 
However, studies evaluating the proteins associated with these glomerular deposits have had 
conflicting results [23, 25].  One study in dogs from the island of Elba found granular 
deposits of IgG, IgM, and C3 within 31 of 34 dogs examined [25].  However, a similar study 
conducted in Brazil found no difference between infected and control dogs in the degree of 
IgG, IgM, or C3 [23]. The latter study did however find a significant increase in the amount 
of L. infantum antigen and inflammatory cells within the GBM and mesangium [23]. Our 
study demonstrates a significant increase in granular to segmental deposits of IgG, C3, and L. 
infantum antigen within both the GBM and mesangium, with no accumulation of IgM.  
Disparities between studies are possibly due to the stage and severity of disease in the animal 
cohorts.  One segment of the cohort used in our study was from a prospective United States 
cohort of dogs studied from 2007 until the present.  Animals in this cohort, even though 
symptomatic, are likely to be identified and euthanized at an earlier stage of disease, prior to 
severe fibrosis and glomerulosclerosis. This may have an impact on the type and density of 
deposits present and the morphologic characteristics of the glomerular lesions. 
  The cytokines IL-1 and IL-18 are major pro-inflammatory cytokines correlated with 
inflammatory renal disease and reperfusion injury in the kidney after ischemia [36]. Renal 
tubular cells are known to secrete IL-1 and IL-18 in response to tubulointerstitial 
inflammation, driving pro-inflammation [36, 47, 48].  This type of inflammation, if present 
within the glomerulus, could be a mechanism for inflammatory cell recruitment and 
significant pro-inflammatory damage to the glomerular filtration apparatus. The role of 
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inflammasome activation in the glomerulus during naturally-occurring infection induced 
MPGN is unknown.  Two studies in murine experimental models that have evaluated NLRP3 
activation within the glomerulus give opposite results.  A single study of the activation of the 
NLRP3 inflammasome during a murine model of anti-GBM disease found little expression of 
NLRP3 mRNA, caspase 1 mRNA, or pro-IL-1 and found renal glomeruli incapable of 
producing NLRP3, caspase 1 protein, or IL-1. However, two other studies have 
demonstrated not only that NLRP3 is expressed by glomerular podocytes, but that NADPH 
oxidase induced NLRP3 inflammasome activation, driving caspase-1, and triggering 
podocyte injury [37]. There have been no other studies, to our knowledge, evaluating the role 
of NLRP3 in glomerular disease, and no previous reports of the presence of NLRP3 
positivity during MPGN. Our study is the first, to our knowledge to associate glomerular 
NLRP3 with the severity of renal lesions and symptomatic MPGN. NLRP3 is a possible 
contributor to glomerular pathology and a possible therapeutic target for inflammatory renal 
disease. 
 Long-lived and metabolically active cells utilize pathways of macroautophagy (self-
eating) for recycling of cellular components via sequestration into double membrane 
autophagosomes with subsequent lysosomal fusion, degradation, and recycling. A related 
form of autophagy, xenophagy, results in uptake and degradation of numerous bacterial, 
viral, and protozoal pathogens utilizing component of the  autophagy machinery, and is 
thought to be essential for the immune response to these pathogens [50]. The role of 
autophagosomes in these cases seems to be to target microbial products to pattern recognition 
receptor bearing compartments, and to facilitate eventual antigen presentation via MHC II 
[51]. Non-canonical autophagy (or LC3-associate phagocytosis) proceeds in the absence of 
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canonical pathway proteins ULK-1 and FIP 200 in response to stimulation through a class III 
PI3K and dependent upon autophagy complex proteins Beclin 1, ATG5, and ATG 7 [52-54].  
This pathway has been demonstrated to be initiated in response to Fc gamma receptor 
engagement by immune complexes, and stimulates NADPH oxidase production in 
macrophages [43]. The formation of LC3-II from LC3-I into its autophagosomal membrane-
associated form, results in a pattern of immunofluorescent staining of discrete puncta, 
indicative of autophagosomes formation [50].  In this study, we have demonstrated for the 
first time the association of renal lesion and disease severity and elevated glomerular 
autophagy in infectious disease-related MPGN.  A single previous study has correlated the 
presence of increased autophagosomes with IgA nephropathy patients, and multiple studies 
have evaluated the role of autophagy for glomerular homeostasis [7, 8, 10, 13]. Elevated 
autophagy has also been identified in a rat model of diabetic nephropathy in response to 
elevated levels of blood glucose [11].  This study is consistent with previous findings and 
elucidates a potential role for glomerular autophagy in response to immune complex 
deposition within the glomerulus. 
 Recent studies suggest that the NLRP3 inflammasome may be induced in response to 
NADPH oxidase in glomerular podocytes and that non-canonical autophagy mediated 
through Beclin 1 is integral to podocyte homeostasis [7, 43].  Macrophages can induce 
NADPH oxidase after engagement of Fc gamma receptor by immune complexes [43].  It is 
possible that the processing of glomerular immune complex deposits is mediated through an 
autophagy pathway and that this process stimulates the induction of IL-1 via the NLRP3 
inflammasome and NADPH oxidase.  However, this study is cross-sectional, and therefore 
the results should be evaluated as such. Detailed experimental models may further elucidate 
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these mechanisms. The strong associations presented within this naturally occurring model of 
MPGN are highly suggestive of a role for glomerular inflammasome activation and 
autophagy in either the induction of or response to glomerular deposition of immune 
complexes and antigen. Therapeutic targeting of these molecules may have potential to limit 
long-term renal damage during MPGN. 
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ABSTRACT 
 Leishmania infantum is a vector-borne obligate intracellular protozoal parasite that 
infects both humans and dogs. The domestic dog is a major reservoir for human infection. As 
such, a vaccine that would prevent transmission between dogs or humans would have a 
significant veterinary and public health impact. Current vaccination strategies for L. infantum 
control in dogs have shown only moderate efficacy and less-than-palatable vaccine site 
reactions with use of saponin-based adjuvants.  To improve upon these previous vaccines, in 
the present study we compared four vaccine modalities based on a synthetic poly-protein 
antigen, Leishmania Vaccine Antigen A (LVAA), with a novel highly immunogenic TLR-
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agonist adjuvant, GLA-SE. Thirty dogs, randomized into 5 experimental groups (n=6/group), 
were immunized to evaluate the immunogenicity and safety of vaccine modalities based on 
LVAA at time 0 (prime) and day 21 (boost).  Peripheral blood mononuclear cells from dogs 
vaccinated with Ad:Pox had significant proliferation and a significant number of cells 
producing IFN in both CD4+ and CD8+ T cell populations upon re-exposure to LVAA 
protein compared to PBMC responses from other groups.  LVAA vaccination did not induce 
a significant increase in IL-10 from PBMC of dogs in any group.  These data suggest that 
LVAA is a strongly immunogenic and safe vaccine candidate for use against visceral 
leishmaniasis in dogs.  Our findings revealed that the Ad:Pox platform was the optimal 
vaccine platform for robust IFN production and T-cell proliferation, signatures of a T helper 
1 response. Further investigation of this candidate vaccine should be pursued to determine its 
clinical potential in dogs. 
 
INTRODUCTION 
 Disease causing Leishmania species are endemic in 98 countries and 3 territories, 
accounting for approximately 2 million human cases and 20-40,000 deaths annually [1].  L. 
infantum causes significant morbidity and mortality in dogs, the predominant domestic 
reservoir of human disease, with canine seroprevalence in areas of Brazil ranging up to 40% 
[1, 2]. Development of an immune response capable of clearing Leishmania spp. infection is 
dependent upon a timely and pronounced Th1 response [3]. Correlates of this response are 
IL-12 production by dendritic cells and macrophages with subsequent presentation of 
parasite antigen on MHC II and CD4+ lymphocyte stimulation toward proliferation and 
production of IFN, with limited production of the Th2-associated or regulatory cytokines 
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IL-4 and IL-10  [4, 5]. In this study we evaluate CD4+ and CD8+ T cell proliferation, IFN, 
and IL-10 intracellular expression and production as a recall response to both vaccine and 
whole freeze-thawed L. infantum antigen (f-t L.i.) as probable correlates of protective 
immunity. 
Current treatment for leishmaniasis primarily uses combinations of a number of 
chemotherapeutic agents.  Pentavalent antimonial agents have been widely used as a first-line 
treatment for VL for decades, and this is reflected by recent increases in antimonial 
resistance [6].  Pentavalent antimony is frequently used in conjunction with allopurinol.  
Amphotericin B is a widely available polyene anti-fungal drug considered the drug of choice 
in areas with antimonial resistance [7]. These two drugs have high rates of severe adverse 
effects and extensive injection-based treatment regimens [8, 9].  Newer formulations of 
amphotericin B into a liposomal form (AmBisome®) has proven to be effective with a single 
dose, but is highly expensive for use in endemic regions [7, 10].  While this and other 
improved chemotherapeutic regimens are in development, recrudescence of disease occurs in 
greater than 65% of dogs following effective chemotherapy [11]. Global management of VL 
in humans and animals may require novel vaccine approaches to develop long-term 
immunity. 
Vaccination for cutaneous leishmaniasis has a centuries-old history, traditionally 
called Leishmanization (LZ), using a small amount of exudate from an infected individual to 
inoculate uninfected persons in an inconspicuous location [12, 13]. This means of 
Leishmania prevention can be quite effective, but the quality control of such approaches is 
greatly deficient [14, 15].  The use of cultured promastigotes for live vaccination is also 
challenging as Leishmania species lose virulence quickly after passage in culture, and thus 
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generate less than optimal host immunity. Whole-killed parasites with adjuvants have been 
used in vaccination trials with poor efficacy [16]. Gene-deletion live vaccines have also been 
pursued with some potential. Centrin-deleted, replication-deficient L. donovani was effective 
in prevention of infection with a challenge exposure to virulent L. donovani in BALB/c and 
SCID mice and in susceptible Syrian golden hamsters [17, 18]. 
One of the only approved canine vaccines in Brazil contains a fucose-mannose ligand 
of L. donovani with saponin adjuvant; resulting in an approximate reduction in clinical 
disease by 60-75% after 2 years [19, 20]. Another canine vaccine, Leish-Tec®, utilized 
adenovirus expression of the A2 amastigote antigen [21, 22]. Second-generation vaccines 
such as Leish-110f (L110f) and other vaccine candidates, are based on using a combination 
of highly immunogenic peptides linked into fusion proteins and administered with adjuvants 
targeted to TLR4 (MPLA or GLA) or TLR9 (CpG DNA) [23, 24].  Most have demonstrated 
protective efficacy in BALB/c mice but, under the conditions tested, were not as effective as 
previously healed infection at preventing Leishmania major infection via sandfly in C57/B6 
mice [25, 26]. A version of L110f, MML, was combined with MPL, tested in dogs, and 
found to be effective in small-scale studies. At the relatively high dose tested in a larger two-
year study, MML was minimally effective in preventing clinical disease as scored and 
defined for that study [27].  L110f with MPL used as immunotherapy with dogs was more 
effective with 90% improvement in clinical signs with 100% of unvaccinated controls having 
no improvement or death by 6 months [28]. 
Vaccination approaches to develop protective immunity against Leishmania spp. have 
been particularly challenging because of immune modulation at the site of infection mediated 
both by the parasite and by the saliva of the sandfly vector [29].  Research into the effects of 
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sandfly saliva in inoculation sites demonstrates an early influx of neutrophils that rapidly 
phagocytize but do not kill the parasite, impairing and skewing the local dendritic cell and 
macrophage response. In addition, parasite-induced alterations in cell signaling results in 
improper dendritic cell maturation and decreased production of IL-12, a key pro-
inflammatory mediator, through enhanced phosphorylation of ERK signaling from the 
phagosome [30]. Therefore, successful immunity may be difficult to achieve through simply 
driving a T helper type 1 response. New approaches to vaccination with improved long-term 
cell-mediated memory responses, improvements in quality control, and a reduction in 
adverse events are needed for prevention of both canine and human VL. An additional 
challenge may also be that in some instances dogs are not infected by sand fly, but via 
maternal, vertical transmission, presenting disease during the time of immune system 
maturation [31]. 
This study evaluates the immunogenicity of a novel Leishmania antigen candidate, 
Leishmania vaccine antigen A (LVAA), based on various modes of activation of the immune 
system in healthy dogs. We will demonstrate that LVAA stimulates a Th1-focused memory 
response capable of a significant recall response up to 2 weeks after vaccine boost across 
multiple vaccine modalities. While vaccination with either an adenovirus vector LVAA with 
protein boost or a adenovirus vector LVAA with canary pox vector LVAA boost induced 
cell-mediated recall responses, we found that adenovirus vector LVAA with canary pox 
vector LVAA boost provided the most pronounced memory response, including cellular 
proliferation, IFN production, and low IL-10.  These data demonstrate that LVAA has a 
strong potential for canine vaccination against L. infantum. 
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MATERIALS AND METHODS 
Sample Population and Study Enrollment – One-year-old female beagles with no prior 
exposure to L. infantum or infected sand flies, housed at Iowa State University, were 
acclimated prior to study initiation. Study animals had complete veterinary standard of care, 
including monitoring throughout the study by licensed veterinarians. Vaccinations were 
administered by licensed veterinarians via single subcutaneous injection, with the exception 
of the DNA vaccine preparation that was administered via intra-muscular injection. Twenty 
milliliters of blood was collected from each dog prior to vaccination and weekly after booster 
vaccination at days 0, 21, 28, 35, and 54. Procedures were performed with approval from 
Iowa State University Institutional Animal Care and Use Committee (IACUC). 
 
Experimental Design and Vaccination Protocol – Dogs were randomized two per enclosure 
with adequate space. Dogs in three enclosures (n=6), were arbitrarily assigned to one of the 
following five experimental groups: 1) placebo (day 0) with placebo boost (day 21) 
(Control), 2) DNA LVAA vaccination (day 0) with LVAA protein boost (day 21) (DNA: 
Protein), 3) LVAA protein with GLA (TLR4 agonist) with LVAA protein and GLA boost (day 
21) (Protein: Protein), 4) LVAA protein expressed by an adenoviral vector (day 0) with LVAA 
protein/GLA adjuvant boost (Day 21) (Ad:Protein), and  5) Adenovirus vector LVAA with 
LVAA expressed within a canary pox LVAA vector boost (day 21) (Ad:Pox).  
 
Vaccine and Adjuvants – Vaccine A antigen in multiple preparations was prepared under the 
proprietary methods of Merial® Animal Health, and GLA adjuvant was prepared separately 
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by the Infectious Disease Research Institute (IDRI) and mixed immediately prior to vaccine 
administration. 
 
Adverse event monitoring – Injection sites were measured via manual examination and 
caliper and examined clinically at 6, 24, 48, and 72 hours post-vaccination.  Reactions were 
characterized by size, location, inflammation, and induration.  These findings were then 
documented and localized reactions (of which there was only one) were photographed for 
documentation.  
 
Sample Handling and PBMC Isolation - Whole blood samples separated into PBMC as 
previously described [32]. Whole blood samples collected in heparin-containing tubes were 
diluted 1:1 with 1x Hank’s Buffered Salt Solution (Cellgro, Manassas, VA) and 25mM 
HEPES .  Diluted whole blood was centrifuged at 800 rcf (Eppendorf, Hauppauge, NY) for 
30 minutes at room temperature through Ficoll/Histopaque 1077 (Sigma Aldrich, St. Louis, 
MO) as previously described [32].  PBMC were counted with an automated cell counter 
(Beckman Coulter, Brea, CA).  PBMC were washed twice in phosphate-buffered saline 
(PBS) and suspended in complete medium (CTCM) (RPMI 1640 supplemented with 10% 
fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM l-glutamine, and 25 
mM HEPES buffer). PMBC were counted and adjusted to 4 × 106/ml for further analysis. 
Cells were then split for evaluation of proliferation and intracellular staining for flow 
cytometry, Griess, or ELISpot Assays. 
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Preparation of parasites and antigen stimulation - L. infantum (LIVT-2) grown for use as 
positive control for kqRT-PCR or freeze-thaw antigen (f-t L.i.) as previously described [32]. 
L. infantum (LIVT-2) was grown in complete Grace's medium (incomplete Grace's 
supplemented with 20% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 2 mM l-glutamine). Parasites were harvested, pelleted at 2500 x g for 15 min at 4°C, 
washed twice with phosphate-buffered salt solution (PBS), and resuspended in PBS to 10
7
 
parasites/ml. Parasites were then flash frozen in liquid nitrogen with subsequent thawing in a 
37
o
 water bath for 3 cycles of freeze-thaw.  Whole f-t L. infantum antigen was quantified to 1 
mg/ml protein concentration via BCA assay (Pierce, Rockford, IL) prior to dilution for 
antigen stimulation. 
 
PBMC Antigen Stimulation - Cells were stimulated with Concanavalin A (ConA; 5 μg/ml) 
for 4 days,  f-t L.i. (10 μg/ml) for 7 days, Vaccine A antigen (10 μg/ml) for 7 days, and 
distemper virus vaccine (Pfizer, Kalamazoo, MI), a non-Leishmania, antigen-specific, 
proliferation control (NSC) for 10 days.  24 hours prior to cell harvest, 5-ethynyl-2´-
deoxyuridine (EdU) (Invitrogen, Grand Island, NY) was added at 10 M, and 10 g/ml 
brefeldin A (Sigma, St. Louis, MO) was added 6 hours before harvest. Cells were harvested 
and washed prior to surface and intracellular labeling.   
 
PBMC immunolabeling – PBMC were labeled with EdU/AF488 for proliferation, CD4, CD8, 
and canine-specific intracellular IFN- and IL-10. Cells were blocked with 25 l of canine 
serum, with mouse and rat non-specific polyclonal IgG at 20 g/106 PBMC for 20 minutes at 
4oC prior to surface receptor labeling. After cell membrane receptor labeling, PBMC were 
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fixed with 1% paraformaldehyde, then permeabilized with saponin permeabilization reagent 
prior to intracellular cytokine labeling (Invitrogen, Grand Island, NY). PBMC were 
preserved in BD stabilizing fixative (BD biosciences, San Jose, CA) and analyzed within 48 
hours. Data was acquired via FACScanto (BD biosciences, San Jose, CA) with FlowJo 
(TreeStar Inc., Ashland, OR). Canine PBMC labeling panel: EdU Click-It (Invitrogen, Grand 
Island, NY), anti-canine CD4/Alexafluor 647 (AbD Serotec, Raleigh, NC), anti-canine 
CD8/Alexafluor 700 (AbD Serotec, Raleigh, NC), anti-canine IFN/Zenon R-PE (R&D 
systems, Minneapolis, MN)(Invitrogen, Grand Island, NY), anti-canine IL-10/Zenon 
APC/Alexafluor 750 (R&D systems, Minneapolis, MN) (Invitrogen, Grand Island, NY), and 
anti-human biotinylated PD-1/PE-Cy7 streptavidin (R&D systems, Minneapolis, MN) 
(eBioscience, San Diego, CA).  
 
ELISpot- PBMC were incubated on plates pre-coated with 500 ng anti-canine IFN or IL-10 
capture antibody (R&D systems, Minneapolis, MN). Cells were plated in duplicate with 4, 2-
fold dilutions starting at 5x105 PBMC/well.  Cells were stimulated with 10 g/ml f-t L. 
infantum antigen or 10 g/ml canine distemper antigen (Pfizer, Kalamazoo, MI) overnight at 
37
o
C and 5% CO
2
. One hundred l biotinylated detection antibody (R&D systems, 
Minneapolis, MN) was added at 0.5 g/ml and incubated overnight at 4
o
C.  Detection was 
accomplished via streptavidin alkaline phosphatase and 5-bromo-4-chloro-3-indoly-
phosphate (BCIP) (Sigma Aldrich, St. Louis, MO).  Spots were counted as an average 
between duplicate wells then as an average over all 4 dilutions, standardized to the number of 
spots per 106 PBMC. All counts were performed with complete blinding. 
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Figure 4.1. Vaccination with LVAA with Adenovirus vector and Canarypox vector 
boost induced CD4+ and CD8+ T cell proliferation after antigen stimulation. PBMC 
were collected from naïve (day 0) and previously primed (Day21; Boost), or previously 
boosted (Day7 pb, Day14 pb) laboratory dogs and stimulated with media (no stimulation, top 
row), 10 g/ml of LVAA vaccine antigen (LVAA, middle row), or 10 g/ml whole f-t L. 
infantum antigen (L. infantum, bottom row) for 7 days. Proliferation was measured via 24 
hour uptake of EdU. A-C) CD4+ T cell proliferation post-stimulation to no stimulation (A), 
LVAA (B), and f-t L.i. (C)  D-F) CD8+ T cell proliferation post-stimulation to no 
stimulation (D), LVAA (E), and f-t L.i. (F). Data was analyzed with GraphPad Prism 5 via 2-
way ANOVA of all treatments over repeated time points with Bonferroni post-test. All 
graphs are shown as population data with error bars as SEM. Statistical analysis: a – Ad:Pox 
group significant over all other treatments (p<0.01); b – Ad:Pox and Ad:Protein significant 
over all other groups (Ad:Pox<0.01; Ad:Protein<0.05). 
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Nitric oxide production – The concentration of nitrite was assessed by the Griess reaction, in 
which 50 µl cell culture supernatant and Griess reagent (LabChem, Pittsburgh, PA) was 
mixed and incubated at RT. The absorbance was measured at 550nm via microplate reader 
(Molecular Devices, Sunnyvale, CA).  Nitrite concentration was determined via a sodium 
nitrite standard curve.  
 
Statistical analysis – Statistical analysis was conducted with one way ANOVA with 
Bonferoni’s post-test for multiple time points via Graph Pad Prism version 5.04 (GraphPad 
Software, La Jolla, CA), significance at =0.05. Graphical data presented as arithmetic mean 
+ SEM. 
 
RESULTS 
LVAA induces pronounced proliferative response in CD4+ and CD8+ T cells 
 To evaluate how well LVAA administered through different modes of immune 
activation induced a T-cell recall response, we exposed PBMC from vaccinated dogs to both 
LVAA antigen and whole freeze-thawed L. infantum (ft-L.i.) antigen at multiple time points 
and evaluated proliferation as measured by EdU incorporation in CD4+ or CD8+ cells 
(Figure 4.1). No experimental group had a proliferative CD4+ or CD8+ T cell recall response 
to either LVAA or f-t L.i. at day 0 or at the time of boost vaccination at day 21.  After boost, 
however, both groups with primary adenovirus vector vaccination (Ad:Protein, Ad:Pox) had 
significantly increased proliferation of CD4+ T cells by day 7 post-boost in response to 
LVAA antigen (Figure 4.1B). This proliferative response was most pronounced at day 14 
post-boost (Figure 4.1B). The CD8+ T cell response to LVAA was similar, with both the  
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Figure 4.2. Vaccination with LVAA preparations induced significant CD4+ T cell 
intracellular and PBMC secretion of IFN. PBMC were collected from naïve (day 0) and 
previously primed (Day21; Boost), or previously boosted (Day7 pb, Day14 pb) laboratory 
dogs and stimulated with media (no stimulation, top row), 10 g/ml of LVAA vaccine 
antigen (LVAA, middle row), or 10 g/ml whole f-t L. infantum antigen (L. infantum, bottom 
row) for 24 hours (ELISpot) or 7 days (FACS).  A-C) Intracellular IFN within CD4+ PBMC 
after 7 days of stimulation with no stimulation (A), LVAA (B), or f-t L.i. (C). D-F) Secretion 
of IFN after 24 hours of culture with no stimulation (D), LVAA (E), or f-t L.i. (F) in total 
PBMC measured via ELISpot. Data was analyzed with GraphPad Prism 5 via 2-way 
ANOVA of all treatments over repeated time points with Bonferroni post-test. All graphs are 
shown as population data with error bars as SEM. Statistical analysis:  b - Ad:Pox and 
Ad:Protein significant over all other groups (Ad:Pox<0.01; Ad:Protein<0.05); c – Ad:Pox 
significantly increased over control (p<0.01); d - Ad:Pox and Ad:Protein significant over 
control (Ad:Pox<0.01; Ad:Protein<0.05); e – All vaccination groups significantly elevated 
over control (Ad:Pox (p<0.01), DNA:Protein, Protein:Protein, and Ad:Protein (p<0.05)). 
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Ad:Protein and Ad:Pox groups having significant CD8+ T cell proliferation at day 7 post-
boost, and only the Ad:Pox having significant proliferation by day 14 post-boost (Figure 
4.1E).  Overall proliferative responses to whole f-t L.i. were only significantly increased in 
the Ad:Pox group in both CD4+ and CD8+ T cells (Figure 4.1C, F). Interestingly, within the 
Ad:Pox group, CD4+ and CD8+ T cells from peripheral blood were undergoing a significant 
degree of proliferation in culture even in the absence of added antigen by day 14 post-boost 
(4.1A, D). This increase in proliferation within the no stimulation group occurs by day 14 
post-boost, occurs in all animals of the Ad:Pox group in both CD4+ and CD8+ T cells, and is 
consistent with IFN production from this experimental group (Figure 4.2A).  This appears to 
be associated with a response to the canarypox vector boost after adenovirus priming. 
Possible explanations for this response are prolonged antigen presentation, or survival of the 
viral vector within cells capable of antigen presentation longer-term after administration [33]. 
With non-specific stimulation subtracted out, the only group with significant antigen-specific 
proliferation was the Ad:Protein group (P<0.01) within the CD4+ T cell population (Figure 
4.1 A, B, C).  
 The adenoviral-vectored preparation, both with protein boost and canary pox-vector 
boost, was capable of proliferative recall responses to previous vaccination. Vaccination with 
adenovirus-vector LVAA with canary pox-vector LVAA boost generates the most robust 
overall proliferative recall response to vaccine antigen and whole L. infantum antigens. In 
addition, the Ad:Protein vaccination platform for LVAA generates the most robust antigen-
specific population at 7 and 14 days post-boost. 
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Figure 4.3. Vaccination with LVAA preparations induced significant CD8+ T cell 
intracellular  IFNproduction. PBMC were collected from naïve (day 0) and previously 
primed (Day21; Boost), or previously boosted (Day7 pb, Day14 pb) laboratory dogs and 
stimulated with media (no stimulation, A), 10 g/ml of LVAA vaccine antigen (LVAA, B), 
or 10 g/ml whole f-t L. infantum antigen (L. infantum, C) 7 days.  A-C) Intracellular IFN 
within CD8+ PBMC after 7 days of stimulation with no stimulation (A), LVAA (B), or f-t 
L.i. (C). Data was analyzed with GraphPad Prism 5 via 2-way ANOVA of all treatments over 
repeated time points with Bonferroni post-test. All graphs are shown as population data with 
error bars as SEM. Statistical analysis:  c – Ad:Pox significantly increased over control 
(p<0.01); d - Ad:Pox and Ad:Protein significant over control (Ad:Pox<0.01; 
Ad:Protein<0.05). 
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LVAA vaccine preparations promote IFN in CD4+ and CD8+ T cells 
 Protective immunity against L. infantum infection is requisite upon a robust Th1 type 
response characterized by pronounced levels of IFN from primarily CD4+ and CD8+ T cells 
. To evaluate the potential Th1 response in dogs vaccinated with LVAA, we monitored recall 
responses in PBMC from dogs vaccinated with LVAA by stimulating PBMC with f-t L.i. and 
LVAA for 7 days in vitro, then evaluating the number of CD4+ and CD8+ IFN T cells. 
Both Ad:Protein and Ad:Pox groups had significantly elevated populations of IFN CD4+ T 
cells compared to other groups in response to LVAA antigen at day 21 pre-boost, day 7 post-
boost, and day 14 post-boost vaccination (Figure 4.2B).  Significant increases at 21 days after 
primary vaccination occurred in both adenovirus-vector primed groups indicating that this 
vaccine formulation generated an IFN response after a single vaccination (Figure 4.2B). In 
response to whole f-t L.i., only the Ad:Pox group demonstrated significant increases in IFN 
at day 14 post-boost (Figure 4.2C).  Similar to cellular proliferation, there was a significant 
increase in IFN CD4+ T cells within the no stimulation group of  the Ad:Pox, primarily at 
day 14 post-boost. Antigen-specific proliferation after subtraction of the no stimulation group 
was significantly elevated in the Ad:Protein group at 7 and 14 post-boost (p<0.01) and in the 
Protein:Protein group at day 7 post-boost (p<0.05) (Figure 4.2A, B, C). 
 The secretion of IFN in response to antigen was evaluated for LVAA and f-t L.i. in 
PBMC from vaccinated and control animals using ELISpot to quantify the number of IFN-
secreting cells per 10
6
 PBMC.  These results demonstrated a significant increase in IFN 
production within both the Ad:Protein group and the Ad:Pox group over all other 
experimental groups day 21 pre-boost, day 7 post-boost, and day 35 post-boost, similar to 
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intra-cellular staining of CD4+ T cells for IFN (Figure 4.2E, F).  This increase was observed 
after both stimulation with LVAA antigen and stimulation with whole f-t L.i (Figure 4.2E, F). 
At day 14 post-boost, IFN production was also significantly elevated in the Protein:Protein 
group (Figure 4.2E, F).  ELISpot analysis for IFN production demonstrated minimal 
changes in the no stimulation group compared to some intracellular IFN- production and 
cellular proliferation in CD4+ T cells. This suggests that while CD4+ T cell proliferation and 
intracellular IFN production were increased in the no-stimulation groups at boost to 14 days 
post-boost, actual secretion of IFN was minimal in the absence of antigen stimulation. 
Discrepancies between results obtained by intracellular staining and ELISpot could be 
attributed to technical differences (incubation times) or functional differences (e.g., 
intracellular processing or secretion of IFN. The ELISpot method measures the 
accumulation of secreted cytokine over the entire incubation period, while intracellular 
staining determines how much intracellular IFN accumulated during a span of 6 hours after 
brefeldin A treatment following 7 days of incubation.  Regardless, dogs vaccinated with the 
Ad:Protein and Ad:Pox had superior Th1-oriented IFN production in response to antigen 
than other groups and Ad:Pox was more consistent and optimal to the Ad:Protein group, 
although not statistically different. 
 Production of IFN by CD8+ T cells after vaccination followed a trend similar to, 
although not as pronounced as that of CD4+ T cells (Figure 4.3). Stimulation of PBMC with 
LVAA at 14 days post-boost induced a significant elevation of intracellular IFN in the 
Ad:Protein (p<0.05) and Ad:Pox (p<0.001) group (Figure 4.3B). IFNproduction after 
stimulation with whole f-t L.i. was significantly elevated only within the Ad:Pox group at day 
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Figure 4.4.  Vaccination with LVAA vaccine preparations resulted in limited CD4+ and 
CD8+ T cell production of IL-10. PBMC were collected from naïve (day 0) and previously 
primed (Day21; Boost), or previously boosted (Day7 pb, Day14 pb) laboratory dogs and 
stimulated with media (no stimulation, top row), 10 g/ml of LVAA vaccine antigen 
(LVAA, middle row), or 10 g/ml whole f-t L. infantum antigen (L. infantum, bottom row) 
for 7 days. Proliferation was measured via 24 hour uptake of EdU. A-C) CD4+ PBMC 
intracellular IL-10 7 days after no stimulation (A), LVAA (B), and f-t L.i. (C).  D-F) CD8+ 
PBMC intracellular IL-10 7 days after no stimulation (D), LVAA (E), and f-t L.i. (F). Data 
was analyzed with GraphPad Prism 5 via 2-way ANOVA of all treatments over repeated time 
points with Bonferroni post-test. All graphs are shown as population data with error bars as 
SEM. 
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14 post-boost compared to the control group (Figure 4.3C). A spike in IFNintracellular 
production in the no stimulation group observed in CD4+ cells and in PBMC as a whole, was 
present, but was not statistically significant in the CD8+ T cell population.  As a whole, 
vaccination of dogs with Ad:Pox LVAA results in significant elevation of intracellular IFN 
in CD4+ and CD8+ T cells and a significant increase in the secretion of IFN from PBMC in 
response to LVAA and whole f-t L.i.  
 
LVAA vaccination strategies do not skew toward IL-10 production after antigen re-
stimulation 
 Vaccine responses skewed toward a Th2 or regulatory T cell response are 
characterized by increased levels of the cytokine IL-10 are associated with reduced Th1 cell-
mediated immune responses, necessary for protection against intracellular pathogens such as 
L. infantum [32, 34] . Furthermore, elevated levels of IL-10 early in infection with 
Leishmania spp. has been associated with increased parasite burdens and increased severity 
of infection [35]. To determine if IL-10 was induced in response to vaccine and f-t L.i., we 
stimulated PBMC from vaccinated and control dogs ex vivo with 10 g/ml of LVAA and 10 
g/ml f-t L.i. for 7 days.  We evaluated intracellular IL-10 by flow cytometry in CD4+ and 
CD8+ populations (Figure 4.4). There were no significant changes in CD4+ IL-10 production 
in response to LVAA or whole f-t L.i. in any group (Figure 4.4a, b, c). Similarly, there were 
no significant elevations in IL-10 from CD8+ T cells compared to control (Figure 4.4D, E, 
F). The DNA:Protein group was significantly elevated in IL-10 production compared to the 
Ad:Protein and Ad:Pox groups at day 28 (Figure 4.4F). None of the vaccine preparations 
induced pronounced elevations in intracellular IL-10.  
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In conjunction with a minimal induction of IL-10, the significant production of IFN and 
CD4+ T cell proliferation indicates optimal immunogenicity toward a Th1 cell mediated 
response in response to Ad:Protein and Ad:Pox LVAA vaccination, with the most 
pronounced responses observed within the Ad:Pox group.   
 
DISCUSSION 
The development of vaccines against some of history’s greatest plagues of animals 
and humans have saved countless lives and resulted in the eradication or near eradication of 
some diseases from the planet, like smallpox and rinderpest. However, chronic intracellular 
infections with pathogens like Mycobacterium tuberculosis, Trypanosoma cruzi, and 
Leishmania spp. have proven significantly more difficult to prevent due to the immune 
escape mechanisms of the pathogen, the complex transmission cycles of zoonotic pathogens, 
and the requirement for enhanced cell-mediated and innate immunity rather than a protective 
antibody response [1, 16, 36]. Historically, active infection with a small number of 
Leishmania spp. parasites, Leishmanization, has resulted in reasonable protection against 
cutaneous leishmaniasis likely due to the persistence of a small number of parasites at the 
lesion site, and a continued release of antigen [12]. This approach is still disfiguring and 
quality control is difficult because active lesions can arise at much later times [15]. The use 
of the complex fucose-mannose ligand of L. donovani with saponin adjuvant (Leishmune®) 
has been moderately effective in reducing clinical disease in dogs with an approximate 
reduction in clinical disease by 60-75% after 2 years [19]. However, while reports indicate 
that Leishmune may inhibit transmission out to 11 months [37], it is less clear if these dogs 
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remain parasitemic and capable of infecting sandflies under real-world conditions long-term. 
The duration of protection with this approach is also short, and there is a high percentage of 
adverse events post-vaccination with Leishmune® [20]. In endemic areas, it is unclear 
whether individual animals receiving the vaccine are truly naïve, and in fact in many regions 
it is highly unlikely that vaccinees have not had previous exposure [31, 38, 39]. Prior 
exposure presents a special challenge, as vaccination may serve more as an 
immunotherapeutic than a prophylactic vaccination.  Another difficulty may be that any 
vaccine must overcome an immune response previously molded by exposure to parasites and 
sandfly saliva. An optimal vaccine candidate must mimic an asymptomatic infection in 
which the infection is cleared. In fact, it must assist clearance in infected, asymptomatic 
dogs. In addition, the vaccination must result in memory responses capable of effectively 
clearing subsequent exposures without establishment of chronic infection.  
Second-generation vaccines utilizing specific combinations of immunogens, such as 
L110f, have demonstrated promising results in mice, resulting in cell-mediated 
immunogenicity in BALB/c and C57/B6 mice with protection, dependent upon experimental 
conditions [24, 25, 40, 41]. Gene-deletion live parasite vaccination strategies have recently 
emerged as a potential avenue to generate an immune response to live infection [17, 18, 42]. 
Centrin-deleted Leishmania donovani, which can replicate as promastigotes in culture, but 
are replication-deficient as amastigotes in the mammalian host, has emerged recently as a 
vaccine candidate [18, 41].  This replication-deficient L. donovani was protective in BALB/c 
mice and Syrian golden hamsters 10 weeks post-challenge [18]. The translation of second 
generation vaccines from rodent models into dogs or humans has proven exceedingly 
difficult. L110f had a limited to moderate efficacy in an endemic region of Italy, without a 
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significant delay in clinical signs compared to controls [27]. Centrin-deleted, live attenuated 
vaccines are similarly immunogenic in dogs, but no challenge studies have been published to 
date [42]. In this study, we have demonstrated the immunogenicity of LVAA in the induction 
of a Th1-focused CD4+ and CD8+ memory response. This response is similar to previous 
studies into recombinant protein sub-unit vaccines in mice and in dogs. LVAA demonstrated 
a significant increase in cellular proliferation and IFN production in both CD4+ and CD8+ 
T cells with a minimal increase in intracellular IL-10. In numerous studies, these 
immunologic parameters are defined correlates of immunity against VL-causing species of 
Leishmania, and while not perfect, the efficacy of LVAA in inducing this type of immune 
signature after vaccination in the target species demonstrates significant potential. 
There was no increase in nitric oxide indirectly measured by the presence of organic 
nitrites via the Griess assay (data not shown, Supplemental Figure 1).  In mice, iNOS2 is 
highly expressed with a large generation of nitric oxide in response to elevated IFN. In dogs, 
elevations of nitrite are very subtle, likely due to species differences, similar to murine and 
human macrophage phenotypic differences, which have been controversially discussed over 
the last decade [43]. Syrian golden hamsters have impaired activation of iNOS as well, due to 
reduced binding of nuclear factor IL-6 (NF IL-6) to the iNOS promoter compared to mice 
[44]. It is possible that canines and humans have similar alterations compared to mice, or that 
aerobic culture conditions are not permissive to iNOS production in humans and dogs, but 
are in murine macrophages, as suggested separately by Bogdan and Nathan [45, 46]. 
Vaccine preparation also has a large influence on the efficacy and safety of 
vaccination. Within this study we analyzed multiple modalities of immune activation by 
LVAA including protein with TLR4 agonist, plasmid containing LVAA-coding DNA, 
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Adenovirus-vector LVAA, and Canary pox-vector LVAA. DNA vaccines have shown 
potential. In theory, these vaccines can induce resident tissues, usually skeletal myocytes and 
antigen presenting cells, to present antigen on both MHC class I and II [47].  However, 
plasmid uptake can be highly variable, and often these vaccines have poor immunogenicity 
compared to traditional protein vaccines [47, 48]. DNA:Protein LVAA vaccine showed some 
indication of priming of CD8+ T cells, possibly through presentation on MHC class I, as 
compared to CD4+ responses to this same vaccine preparation. However, plasmid 
incorporation may have been inconsistent, as 3 dogs (50% of the group) demonstrated 
significant levels of proliferation (39%, 51.7%, and 14.4% of CD4+ T cells; 46%, 46.3%, 
and 9.72% of CD8+ T cells) and IFN production (21.6%, 27.3%, and 9.72% of CD4+ T 
cells; all groups CD8+ T cells >20%), and 3 dogs (50% of the group) had almost no 
proliferative response (<5% in both CD4+ and CD8+ T cells) and minimal CD4+ T-cell 
intracellular IFNin CD4+ T cells). It may be possible to improve this vaccine 
preparation although the viral-vectored and protein vaccine preparations were significantly 
more immunogenic.  
For some of the analyses LVAA protein used either in heterologous prime-boost 
experiments or in adenovirus only form performed better than using only LVAA protein 
formulated with the GLA adjuvant. However, in other cases such as IFN ELISpot assays, 
Protein:Protein appeared to require boosting, but ultimately resulted in equivalent numbers of 
cells producing IFN as the heterologous prime-boost groups.  Previous studies of second-
generation candidates such as L111f/L110f and KSAC have utilized fusion protein plus TLR 
agonist for vaccination demonstrating protection in mice and hamsters [23-26, 41]. The 
subunit polyprotein antigen L111f, when combined with the TLR4 agonist in stable emulsion 
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MPL-SE, has provided moderate to limited immunotherapeutic cure in dogs [28],  and the 
related subunit polyprotein antigen MML gave moderate to limited protection [27].  The 
results of our study are consistent with the previous reports for L111f and MML.  
LVAA protein used directly with the GLA adjuvant was less efficient at priming a 
Th1 response during this experiment compared to other preparations. Previous studies of 
second generation candidates such as L110f have utilized fusion protein plus TLR agonist for 
vaccination demonstrating some protection in mice and hamsters [23-26, 41]. However, 
subunit polyprotein vaccines with TLR4 agonists have had limited protection and 
immunotherapy in dogs [27]. The results of this study are consistent with these previous sub-
unit vaccine reports.  
Viral vector vaccine preparations using replication-deficient adenovirus vectors are 
highly immunogenic, as the adenovirus capsid and genome illicit strong responses to the 
expressed antigen [49-51].  Adenovirus preparations were only used as priming vaccinations 
in this study due to the risk of immune focusing toward dominant vector-derived antigens 
and not LVAA polyprotein. Adenoviral-vector LVAA priming with protein or canary pox-
vector LVAA boost were significantly the most immunogenic vaccine preparations for both 
CD4+ and CD8+ T cells and for whole PBMC secretion of IFN. This demonstrates that 
adenoviral-vectored vaccines in this study provided the most effective priming vaccination. 
Canarypox virus vectors for vaccination are unique and have the advantage of being 
replication deficient, of having very large vectoral capacity, and engage the innate immune 
system, including Type I IFN induction, activation of inflammasome pathways, and 
induction of NFB signaling [52]. However, it is remarkable how little is known about how 
canarypox viruses interact with the innate immune system [52]. Canarypox-vector LVAA 
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performed the best over other groups as a boost vaccination to Adenovirus-vector LVAA 
primary vaccination. We did observe prolonged proliferation of CD4+ T cells in non-
stimulated groups up to 14 days post-vaccination (Figure 4.1, 2) with this treatment. With 
this non-specific proliferation subtracted, the Ad:Protein platform generated the most 
consistent responses of cellular proliferation and IFN It is unlikely that the non-specific 
proliferative response of the Ad:Pox group was due to a comorbid disease in these dogs as it 
occurred in all dogs of one experimental group, housed in three different kennels, and in no 
animals of other groups. It is also unlikely that this finding could be due to experimental 
error because both proliferative and IFN responses were elevated in all animals of this group 
across two time points and in no other experimental group (Figure 4.1, 2). It is possible that 
the induction of a pronounced Th1 response may have been due to the persistence of LVAA 
secretion, even in the absence of viral vector replication. 
This study demonstrates the immunogenicity of LVAA antigen with an Adenoviral-
vector LVAA prime and LVAA protein/GLA or canary pox-vector LVAA boost.  The most 
pronounced overall Th1 response was observed within the Ad:Pox group and the greatest 
antigen-specific Th1 response in the Ad:Protein group, as demonstrated by a proliferative 
response and IFN production in response to LVAA antigen and whole f-t L.i. in both CD4+ 
and CD8+ lymphocytes. Our data, generated using several different formulations, support 
LVAA as a vaccine antigen that appears suitable for the prevention of canine leishmaniasis. 
Further studies to evaluate the efficacy of the Ad:Pox and the Ad:Protein LVAA protocols 
under challenge conditions in dogs are warranted. 
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Supplemental Figure 1. Vaccination with LVAA vaccine preparations resulted in 
limited PBMC nitrite production ex vivo. PBMC were collected from naïve (day 0) and 
previously primed (Day21; Boost), or previously boosted (Day7 pb, Day14 pb) laboratory 
dogs and stimulated with media (no stimulation, A), 10 g/ml of LVAA vaccine antigen 
(LVAA, B), or 10 g/ml whole f-t L. infantum antigen (L. infantum, C) for 24 hours. Cell 
supernatants were harvested for the Greiss assay indirect measure of iNOS activity. A-C) 
nMol of organic nitrite (106) in response to no stimulation (A), LVAA (B), and f-t L.i. (C). 
Data was analyzed with GraphPad Prism 5 via 2-way ANOVA of all treatments over 
repeated time points with Bonferroni post-test. All graphs are shown as population data with 
error bars as SEM. 
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CHAPTER 5  
GENERAL CONCLUSIONS 
 
SUMMARY 
 The work presented in this thesis contains novel characterizations of the immune 
response to and immunopathology of visceral leishmaniasis. Within the first section is the 
first characterization of functional pan-T cell exhaustion during naturally-occurring visceral 
leishmaniasis, mediated by co-inhibitory receptor Programmed Death 1 (PD-1) and its 
interaction with ligand B7.H1 on antigen presenting cells. This data suggests that during 
chronic infection with Leishmania infantum both CD4+ and CD8+ T cells develop immune 
exhaustion, characterized by impairment of proliferative potential and IFN production from 
CD4+ and CD8+ T cells, and elevation in IL-10 production from CD4+ T cells. All animals 
categorized as symptomatic had CD4+ and CD8+ T cell populations with characteristics of 
functional exhaustion. Within the VL asymptomatic population nearly one half of animals 
had phenotypically exhausted CD8+ T cell populations. Similarly, nearly one half of the 
CD4+ T cell population demonstrated impaired IFN production, but still proliferated in 
response to L. infantum antigen. These functional changes were associated with a significant 
elevation in co-inhibitory receptor PD-1. Pan-T cell exhaustion was also associated with 
phenotypic alterations in monocyte-derived macrophages, with impaired production of 
superoxide and decreased parasite killing, recovered by blockade of PD-1/B7.H1. 
 Blockage of the PD-1 ligand B7.H1 on antigen presenting cells recovered CD4+ and 
CD8+ T cell proliferative capacity.  A partial recovery of IFNproduction was achieved after 
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B7.H1 blockade within the CD4+ T cell population. However, within the CD8+ T cell 
population, only IL-10 blockage resulted in a slight but significant recovery of  
IFNproduction.  Stimulation with L. infantum antigen did not result in increased apoptosis 
in either CD4+ or CD8+ T cell populations, suggesting that the process of T cell exhaustion 
leads to the survival of a non-responsive, antigen-specific T cell population, whose effector 
function is partially recoverable by blockade of PD-1/B7.H1 or IL-10. 
 Immunopathology during infection with multiple different Leishmania spp. is well-
recognized [1, 2]. To date, the understanding of VL immunopathology has been limited to 
over-expression of immuno-inhibitory cytokines (like IL-10), the suppressive functions of 
regulatory T cells, and parasite-derived mechanisms of immune evasion [1, 3-5].  While all 
of these contributions are unambiguously integral to VL pathogenesis and immunity, 
therapeutic or preventive approaches targeting these discoveries have only been moderately 
successful [6-8].  This indicated additional, previously unrecognized, immunopathology 
during VL. The data presented in the first section of this thesis contributes additional novel 
components to pathogenesis of symptomatic VL.  Targeting PD-1 and IL-10 blockade singly 
or in combination in conjunction with pharmacologic intervention, may improve long-term 
outcomes and immunity. In addition, the research presented here may lead to the evaluation 
and/or identification of additional mechanisms of co-inhibition necessary for the precipitation 
of symptomatic VL. 
 Immunopathology during symptomatic VL is associated with excessive production of 
IgG and subsequent hypergammaglobulinemia [9]. This serum chemistry abnormality is 
present during symptomatic VL in both dogs and humans, and thought to be responsible for 
the formation of rheumatoid factors and the development of immune complex-mediated 
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glomerulonephritis [10-12]. Previous reports of VL-associated glomerulonephritis provided 
conflicting accounts of the pathogenesis and classification of the glomerular lesions and the 
components of protein deposits within the glomerular basement membrane [13-15]. The 
study presented in the second section of this thesis utilized routine histologic, ultrastructural, 
and immunohistochemical analyses to classify VL-associated glomerulonephritis as a Type I 
membranoproliferative glomerulonephritis (MPGN) with segmental subendothelial and 
mesangial deposits composed of L. infantum antigen, IgG, and C3. In addition 
tubulointerstitial regions of the kidney contained moderate to severe lymphoplasmacytic and 
histiocytic inflammation with occasional intrahistiocytic L. infantum parasites.  
 Chronic renal disease is a major cause of morbidity and mortality in the world, and is 
the ninth leading cause of death in the United States [16, 17]. In addition, approximately $33 
billion USD in health care expenditures are directed toward the therapy of renal disease each 
year [17]. Glomerulopathy due to numerous different causes is a major cause of functional 
impairment of the kidney and subsequent end stage renal disease (ESRD). The response to 
accumulated protein and immune complexes in the glomerular basement membrane by three 
major cell types that construct and maintain the glomerular filtration apparatus (podocytes, 
mesangial cells, and glomerular capillary endothelial cells) is incompletely understood. 
Macroautophagy is a cellular processing mechanism necessary for the basal function of 
podocytes and mesangial cells [18, 19]. Pro-inflammatory cytokines IL-1 and IL-18 are 
known to promote renal inflammation [20, 21]. However, the role of the NLRP3 
inflammasome and the source of these pro-inflammatory cytokines is unknown.  Using 
naturally-occurring canine VL as a model of Type I MPGN, we evaluated the presence of 
autophagosomes identified as “LC3 puncta” and of NLRP 3, a protein associated with the 
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NLRP3 inflammasome in glomerular cells from normal, asymptomatic, and symptomatic VL 
dogs. The level of autophagy and the amount of NLRP3 were both significantly elevated in 
both asymptomatic and symptomatic VL dogs compared to controls. Levels of both proteins 
were also significantly elevated in symptomatic VL compared to asymptomatic dogs. This 
was consistent in both formalin-fixed paraffin embedded and frozen cryosections. While it 
was impossible to elucidate causation from this retrospective cross-sectional study, this data 
strongly supports a role for macroautophagy and the NLRP3 inflammasome as either 
precipitating factors for or a response to immune-mediated glomerular disease. 
 Achieving effective prevention against VL will require the stimulation of cell-
mediated immunity, including CD4+ T cell immunity, capable of parasite clearance prior to 
the initiation of established infection.  In addition, since the exposure rate of patients within 
endemic regions is likely high, such a vaccine would also have to serve as an effective 
immunotherapeutic in previously exposed or asymptomatically infected persons. The 
mechanisms of immunopathology characterized within the first two sections of this thesis 
may further complicate the achievement of effective immunity. At the present, correlates of 
protective immunity for prevention of VL are thought to be robust CD4+ and CD8+ memory 
T cell proliferation and production of IFN in response to L. infantum antigen [8]. 
 In the third section of this thesis we evaluated the immunogenicity of a novel 
proprietary polypeptide vaccine against canine leishmaniasis (CanL), Leishmania vaccine 
antigen A (LVAA), in multiple platforms. We discovered that LVAA has exceptional 
potential as a vaccine candidate for CanL, resulting in significant proliferation and 
production of IFN in both CD4+ and CD8+ T cell populations in the Ad:Pox group 
compared to PBMC responses from other groups.  LVAA vaccination did not induce a 
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significant increase in IL-10 from PBMC of dogs in any group.  This study demonstrates a 
pronounced effector memory response to LVAA vaccination, and further studies may 
elucidate the potential efficacy of LVAA under field conditions. 
 
DISCUSSION 
Immunopathology of visceral leishmaniasis 
 Immunity against Leishmania infantum requires a robust Th1 response, including 
clonal expansion and proliferation of CD4+ T helper cells and the production of pro-
inflammatory cytokine IFN. To achieve such a response, memory T cell populations must 
be present and responsive, dendritic cells and other antigen presenting cells must process and 
present antigen to these T cells, and infected macrophages in turn, must be stimulated to 
generate RNI and ROI capable of killing intracellular parasites. Parasite-derived mechanisms 
of host evasion are common. Two host evasion strategies are parasite surface expression of 
phosphatidylserine using so-called apoptotic mimicry to target alternatively activated 
macrophages, and the induction of phagocytosis by neutrophils for subsequent clearance by 
alternatively activated resident macrophages in a “trojan horse”-like manner [22][23].  
Another is the alteration of dendritic cell phenotype via ERK 1/2 signaling and subsequent 
impairment of dendritic cell IL-12 production [24]. Effective preventive vaccination must be 
able to overcome these immune evasion strategies. As infection progresses, a sterile cure 
with effective long-term immunity is even more difficult to achieve.  Previously initiated 
immune dysregulation including potential Th2 skewing, the preferential infection of 
alternatively activated macrophages, and pan-T cell exhaustion during asymptomatic and 
symptomatic infection that is described in the first section of this thesis become exceedingly 
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difficult to overcome as parasite numbers increase and disease progresses to a clinical state.  
Therefore, the goal of reaching a sterile cure or a truly preventive vaccine for VL by simply 
initiating a robust T helper cell response may be very difficult without additionally targeting 
immune evasion strategies of the parasite and host immunopathology. 
 Immune exhaustion has been previously characterized during various different 
chronic infections as a step-wise loss of function of T cells in response to specific antigen. 
Based on the characterization of exhaustion presented in this thesis, it is apparent that pan-T 
cell exhaustion is present during naturally-occurring VL. CD4+ T cell exhaustion in VL 
seems to be correlated with the onset of symptomatic disease.  However, within the CD8+ T 
cell population, exhaustion was common in the asymptomatic cohort as well.  Our hypothesis 
from this data is that functional T cell exhaustion present during asymptomatic infection aids 
in the transition from asymptomatic infection to symptomatic VL. This could be either a 
host-derived immunopathology developed from the inability to control infection with 
Leishmania infantum, or induced by the parasite directly as a means of host evasion.  Our 
data indicates substantial CD8+ T cell exhaustion prior to the onset of CD4+ T cell 
exhaustion during VL.  This is an interesting finding, considering the primary source of 
antigen from the parasite would be through the phagolysosomal system and presented via 
MHC II to CD4+ T cells.  It is possible that CD8+ T cells are more sensitive to exhaustion, 
as a mechanism of host protection to prevent direct cytotoxic T cell mediated autoimmunity.  
It is also feasible that while antigen is being presented continually to both populations, 
presentation to CD8+ T cells via MHC I occurs with inadequate co-stimulation or at a 
threshold of antigen presentation capable of inducing CD8+ T cell exhaustion. Dysregulation 
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of the immune system via pan-T cell exhaustion mediated by PD-1 is likely a major 
component of immune compromise leading to symptomatic VL. 
 
Immune complex-mediated membranoproliferative MPGN 
 Excessive production of IgG and high levels of circulating L. infantum antigen are 
characteristic of symptomatic VL, and are predictive of the onset of symptomatic disease [9]. 
The formation of immune complexes of IgG and antigen were previously believed to be 
responsible for VL-associated renal disease. Studies evaluating this have had conflicting 
results [13, 14]. The second section of this thesis characterized VL-associated 
glomerulonephritis as a Type I membranoproliferative glomerulonephritis with segmental 
deposits of L. infantum antigen, C3, and IgG.  These findings were associated with 
lymphoplasmacytic and histiocytic interstitial nephritis.  Lesions consistent with these 
changes were identified in both asymptomatic and symptomatic animals.  Previous reports 
have identified the importance of canonical autophagy in maintenance of the glomerular 
filtration apparatus [19]. Separate studies demonstrated that dendritic cells respond to 
immune complexes via the induction of non-canonical autophagy [25]. Our data clearly 
shows an increase in autophagy associated with infection with Leishmania infantum. Our 
hypothesis is that the response of glomerular podocytes and mesangial cells to immune 
complex deposition during glomerular pathologic insult occurs via a non-canonical 
autophagy pathway, separate from the basal organelle and protein recycling functions of the 
canonical pathway. It is also unknown whether immune complexes directly induce 
macroautophagy, or if the elevations seen in our study were the response of glomerular cells 
to ER stress.  The formation of LC3+ compartments in an elevated number of glomerular 
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cells indicated an essential role for autophagy in either the direct response to immune 
complex deposition or as a mechanism to manage cellular stress within the glomerulus. 
Targeting of this pathway may be beneficial in either case to improve the clearance of 
deposited protein or limit the long term damage of immune complex deposition to the 
glomerular filtration apparatus. 
 NLRP3 is a protein associated with inflammasome formation in response to multiple 
different cellular stressors [26].  In response to inflammasome activation, the cleavage of 
Caspase 1 leads to the cleavage of pro-IL-1 to form active IL-1. IL-1 and IL-18 are 
known to be associated with tubulointerstitial renal inflammation, although their role in 
glomerulonephritis is poorly understood [20, 27, 28].  The second chapter of this thesis 
demonstrated significant induction of NLRP3 within the glomerulus during VL-associated 
MPGN in both symptomatic and asymptomatic animals. Similarly to LC3, this induction 
could be either a direct result of immune complex deposition or a response to cellular stress.  
In either case, the significant induction NLRP3 likely contributes to the pro-inflammatory 
environment and further impairment of glomerular function.  
 Recent reports suggest that autophagy and inflammasome function may be linked as 
well. Harris et al. eloquently demonstrated the regulation of IL-1 by autophagy at two 
levels, via degradation of pro-IL-1 and of NLRP3 directly [29]. In another study, Shi et al. 
discovered the targeting of ubiquitinated inflammasomes for degradation within an 
autophagy pathway [30]. Immune complexes are known to stimulate collagen production and 
pro-inflammatory signals by mesangial cells through the engagement of Fc gamma receptor I 
and III [31]. Fc gamma receptor engagement generates ROS via NADPH oxidase targeting to 
LC3+ autophagosomes [32]. It is possible that Fc gamma receptor engagement induces 
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autophagy targeting of immune complexes, and that the induction of ROS primes NLRP3 for 
inflammasome activation. It is also possible that active NLRP3 is targeted for degradation 
within LC3+ autophagosomes. It is impossible however, to test these hypotheses in our 
current model or research as a part of this dissertation, but a plausible hypothesis could be 
made that immune complex deposition induces both NLRP3 inflammasome and LC3+ 
autophagy and that these contribute to glomerular inflammation and damage and preservation 
of the glomerular filtration apparatus respectively. 
 
FUTURE STUDIES 
 Given the presence of pan-T cell exhaustion during VL, which was only partially 
responsive to blockade of PD-1 or IL-10, the logical pursuit of future studies is to determine 
additional co-inhibitory mechanisms responsible for the suppression of immune responses 
during exhaustion.  The hypothesis could be made that additional known co-inhibitory 
receptors such as Cytotoxic T-lymphocyte antigen 4 (CTLA-4), T-cell immunoglobulin 
domain and mucin domain 3 (TIM-3), or Lymphocyte-activation gene 3 (LAG-3) may also 
contribute to functional exhaustion in this cohort. This could be evaluated by continuing the 
current project with a series of blocking experiments ex vivo to determine the contributions of 
each, with the goal of targeted therapeutic recovery of T cell immunity. Other experiments to 
determine distinct signaling mechanisms responsible for the induction of exhaustion could 
also be performed ex vivo. A proposed study would be to negatively select T cells from 
symptomatic VL and vaccinated uninfected dogs, stimulate them with bead-bound CD3 and 
bead-bound B7.H1 Fc fusion protein, or CD3 alone, to evaluate TCR signaling in response to 
CD3 ligation in these respective populations.  Targets would include signaling through PI3K 
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and negative regulation of Akt through the inhibitory molecule PTEN. Additionally, these T 
cells could be further phenotyped to determine their resemblance to T regulatory cells with 
expression of CD25 and FoxP3. Our current study also demonstrates alterations in 
macrophage phenotype induced by interaction with exhausted T cells.  The mechanisms of 
this alteration are unknown.  Using an in vitro model to induce T cell exhaustion in 
negatively selected T cells populations via bead-bound CD3 and B7.H1, evaluation of 
macrophage function after co-incubation would be possible.  With mitogenic or antigenic 
stimuli, macrophage function could be evaluated in direct co-culture or in transwell to 
determine the necessity of receptor-ligand and bystander interactions.  Also, a further defined 
transcriptomic evaluation of these exhaustion-impacted macrophages would be possible, to 
compare to previously characterized macrophage phenotypes. The proposed studies would 
add significantly to the base of knowledge of the immunopathology of visceral leishmaniasis 
and of T cell exhaustion. 
 The second section of this thesis demonstrates the potential involvement of NLRP3 
and LC3+ autophagy in immune complex-mediated MPGN. The data presented in this cross-
sectional cohort is purely associational and not causative, and future studies would be 
directed toward a mechanistic understanding of these two processes in MPGN.  First, further 
defining the specific cell types conducting autophagy and NLRP3 inflammasome formation 
is paramount to understanding the pathogenesis of MPGN and is currently unknown.  The 
utilization of podocyte-specific markers such as podocin and nephrin and a combination of 
smooth muscle actin, alpha-5 integrin, and dectin for mesangial cells would be sufficient. In 
addition, planned experiments using laser capture microscopy to identify transcriptional 
alterations related to the NRLP3 inflammasome and canonical and non-canonical autophagy 
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pathways will further elucidate the specific role of these pathways in MPGN. Specific 
cellular markers could be integrated into the laser capture microscopic procedure, using 
immunofluoresence to identify cells for capture.  Subsequent studies will require the 
utilization of genetically engineered mice and perhaps a transition to a traditional 
experimental model of immune complex-mediated MPGN.  Utilization of existing podocyte-
conditional LC3 -/-, Fc gamma receptor 1-/-, Beclin 1-/-, and NLRP3-/- mice with the 
evaluation of lesion severity and immune complex deposition within the GBM, and 
alterations in renal function between genetically modified mice and wild-type mice would 
further identify causation versus association, and the role of canonical versus non-canonical 
autophagy in the response to immune complex deposition.  
 As a whole the research presented within this thesis contributes significantly to 
knowledge of asymptomatic and symptomatic VL.  In addition, this research provides new 
avenues for extensive experimental research, all of which could be targeted toward 
therapeutic applications.  These include the enhancement of immunity for prevention of VL, 
the recovery of immunity after exhaustion, the promotion of immune complex clearance 
from the glomerular filtration apparatus, and the mitigation of glomerular inflammation to 
provide improved long term outcomes after therapy.  These long-term goals and research 
endeavors would contribute significantly to our knowledge of VL immunopathology and 
renal pathophysiology, and improve human and canine health.    
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APPENDIX 
 
 
 
 
 
Figure A1. Model of pan-T cell exhaustion during visceral leishmaniasis – Naïve T cell 
population encounter Leishmania infantum at the time of infection.  Exposure to a low 
parasite number and clearance results in memory T cell population capable of responding to 
subsequent infection or antigen via production of IFN, proliferation, with low expression of 
PD-1. With asymptomatic infection, CD8+ T cell populations from approximately 50% of 
these subclinically infected patients demonstrate characteristics of exhaustion, with impaired 
proliferation, impaired IFNproduction, and elevated surface expression of PD-1. With 
asymptomatic infection, CD4+ T cell populations are largely responsive, with approximately 
50% of patients having impaired IFN only, with low PD-1 positivity. With persistent 
infection, including elevated parasite burden and seroconversion, pan-exhaustion ensues, 
with high IL-10, elevated PD-1 surface expression on both CD4+ and CD8+ T cells, and 
impaired T cell proliferation and IFN production in response to f-t L. infantum. With 
blockade of IL-10 or PD-1/B7.H1, a partial recovery of T cell functions is possible. 
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